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Inhibition of reverse transcriptase (RT) is a vital tactic in the prevention of human 
immunodeficiency virus 1 (HIV-1).  Nonnucleoside reverse transcriptase inhibitors (NNRTIs) 
are a class of compounds demonstrated to act as allosteric inhibitors of RT DNA polymerization.  
However, several lines of evidence suggest that polymerization may not be the main mechanism 
of inhibition of reverse transcription.  It has been demonstrated that NNRTIs also have the ability 
to modulate RT ribonuclease (RNase) H cleavage.  Additionally, recent evidence suggests that 
resistance to chain-terminating nucleoside reverse transcriptase inhibitors (NRTIs) is dependent 
on a balance between the polymerase and RNase H activities of the enzyme.  In light of this, I 
hypothesize that NNRTIs block reverse transcription by exerting effects on both the DNA 
polymerase and RNase H active sites of the enzyme, significantly disrupting the equilibrium 
between these two enzymatic activities. Therefore, the ability for NNRTIs to be combined with 
other classes of RT inhibitors in antiretroviral therapies will depend on how these compounds 
respond to the NNRTI-induced shift in the polymerase/RNase H activity equilibrium. This study 
demonstrates that NNRTIs cause the accelerated appearance of secondary RNase H cleavage 
products that have decreased RNA/DNA hybrid structures.  As a result, these template/primers 
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(T/Ps) are not sufficient substrates for NRTI removal and therefore, excision is less efficient in 
the presence of NNRTIs.  Additionally, fluorescent resonance energy transfer experiments 
demonstrate that NNRTIs cause a shift in the binding of RT and T/P such that the RNase H 
domain is moved away from the 5’end of the primer.  Finally, subunit-specific analysis shows 
that resistance to RTI combination therapy facilitated by the N348I mutation is a result of effects 
from the p51 subunit.  I propose that the binding of NNRTIs cause RT to bind to T/P in a 
polymerase-incompetent mode, resulting in decreased polymerization and shorted RNase H 
cleavage products.  Additionally, N348I can facilitate dual resistance by favoring the 
polymerase-competent binding mode.  This work is of public health significance because it lays 
the foundation for the development of new reverse transcriptase inhibitors and highlights the 
importance of resistance in the connection domain of HIV-1 RT. 
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1.0  INTRODUCTION 
 
1.1 HUMAN IMMUNODEFICIENCY VIRUS 
1.1.1 HIV-1 Origin 
Four independent interspecies crossover events of simian immunodeficiency virus (SIV) have 
shown to be the origin of the human immunodeficiency virus type 1 (HIV-1) pandemic in 
humans [1].  Phylogenetic relationships have indicated that HIV type 1 and  type 2 arose from 
the closely related SIV-infected chimpanzees (Pan troglodytes troglodytes) and sooty mangabeys 
(Cercocebus atys), respectively.  The evolution of HIV-1 led to four distinct phylogenetic groups 
termed M (main), O (outlier), N (non-M, non-O) and P (putative) [1-2].  The origins of group M 
can be traced back to chimpanzees in Cameroon while group O seems to be prevalent in gorillas 
(Gorilla gorilla) in the same region [3].  The origins of groups N and P are still unknown.   
HIV-1, the causative agent of acquired immunodeficiency syndrome (AIDS), has a high 
replication rate, producing 109 to 1010 virions per day, and a high mutation rate, approximately 
1.4 x 10−5 per nucleotide base per cycle of replication, resulting in extreme heterogeneity and a 
very complex pattern of evolution within the host [4].  These genotypically related viruses within 
one host comprise a quasispecies [5].  As a result, three of the four groups have diverged into 
numerous subtypes since the early 1900s [6].  Group M, being the most widespread, has 
expanded into nine subtypes including A-D, F-H, J and K.  Phylogenetic analyses have shown 
that overall these subtypes have 70-90% sequence similarity (diversity is 20-30% in env, 15-22% 
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in gag and 15% in pol) [7].  Subtypes A-D are responsible for 90% of today’s current pandemic, 
with subtype B being most prominent in the industrialized world (12% of worldwide infections) 
and subtype C being the most prevalent overall (50% of world-wide infections) [7].  
Additionally, at least 21 subtype circulating recombinant forms (CRFs) have been identified [8].   
1.1.2 HIV-1 Structure 
HIV-1 is a lentivirus in the retroviridae family.  As with other viruses in this family, HIV-1 has 
an outer layer derived from its host cell plasma membrane which can contain up to 200 copies of 
the envelope glycoprotein (gp160).  In its native form on the surface of a virion, the envelope is a 
heterotrimer consisting of three gp120 molecules and three gp41 molecules.  The gp120 and 
gp41 molecules interact through non-covalent interactions [9].  The gp120 molecule binds to the 
receptors on the target cells while gp41 is involved in fusion.  In a mature virion, just below the 
surface of the outer shell, is a layer of matrix (MA, p17) followed by a cone-shaped core formed 
from capsid (CA, p24), which protects the innermost contents of the virion, and the p6 protein 
(Fig. 1).  The content of the core includes two copies of the RNA genome protected by a coating 
of nucleocapsid protein (NC).  The core also contains the non-structural proteins reverse 
transcriptase (RT) and integrase (IN), in addition to viral protein R (Vpr), and host cell factors 
[10].  The protease (PR) is found within the virion but outside the core structure.  The viral 
infectivity factor (Vif) and negative factor (Nef) accessory proteins are found closely associated 
with the core of the virion. 
 3 
 
Figure 1. The human immunodeficiency virus structure. 
Shown are all virion components.  The listed proteins are found in the virion but are not pictured.  Adapted from an 
open source (http://amath.colorado.edu/index.php?page=hiv-early-infection-pathogenesis-modeling). 
1.1.3 Virus Life Cycle 
1.1.3.1 Binding and Fusion 
Despite the fact that HIV-1 is able to infect a variety of cell types, AIDS is largely the result of 
depletion of CD4+ T cells.  As mentioned above, the process of viral replication begins with the 
binding of gp120 to the CD4 receptor (Fig. 2, step 1), causing a structural change in both 
molecules and exposing the chemokine co-receptor binding site.  This allows the engagement of 
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a chemokine receptor expressed at the cell surface, depending on the tropism of the virus.  HIV-1 
most commonly uses the CCR5 (R5) or CXCR4 (X4) co-receptor for viral entry and this tropism 
is dictated by the sequence of the V3 and V1/V2-variable regions of gp120.  The hydrophobic 
ectodomain of the N-terminal fusion peptide, gp41, can then penetrate the cell membrane, 
leading to fusion of the two and allowing release of the viral core into the cytoplasm of the cell 
(Fig. 2, step 2). 
1.1.3.2 Uncoating and Reverse Transcription 
After virus entry, a process known as uncoating occurs (Fig. 2, step 3).  The capsid core 
undergoes morphological changes in the cytoplasm, and the subunits are disassociated from the 
viral genome [11-12].  Proper uncoating appears to be essential for efficient HIV-1 infection and 
nuclear import and requires host cell factors [13-14].  For example, cyclophilin A has been 
shown to increase viral infectivity by its interaction with capsid during uncoating [15].  
Conversely, host factors present in certain mammalian cell types cause restrictions to infection at 
the step of uncoating [16].   
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Figure 2.  HIV-1 life cycle. 
The HIV-1 life cycle begins with virus attachment to the host cell receptors (step 1).  The virus envelope then fuses 
with the host cell membrane to allow entry of the viral contents into the cytoplasm (step 2).  Uncoating and reverse 
transcription occur in the cytoplasm (step 3) and then the cDNA is imported into the nucleus.  The viral cDNA is 
integrated into the host genome (step 4) and the viral RNA is produced by the cellular machinery (step 5).  
Translation in the cytoplasm is also performed by the cellular components (step 6) and the viral polyproteins 
assemble at the cell surface.  Immature particles bud from the cell (step 7) and as the viral polyproteins are cleavage 
by the viral protease, the virion matures and becomes infectious (step 8). 
 
Reverse transcription is the process whereby the single-stranded plus-sense RNA genome 
is converted to double-stranded cDNA for integration into the host genome.  Despite a lack of 
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detailed understanding of the timing of initiation of reverse transcription, evidence suggests it is 
coupled with uncoating [17].  At some point between viral entry into the host cell and 
completion of viral cDNA, reverse transcription complexes (RTCs) are formed.  The association 
of RT, viral RNA (vRNA) and the tRNALys3, the minimal components of the RTC, is thought to 
occur in the virion prior to fusion with the host cell [18].  Live cell imaging of HIV-1 through the 
labeling of Vpr and IN suggests that, once in the target cell, the RTC associates with the 
cytoskeleton [19].  Recent studies done with fluorescence microscopy have shown that the RTC 
is attached to the microbules and is actin-dependent, but the viral proteins that interact with the 
host cell transport machinery are unknown [20].  This association seems to require CA subunits, 
but is shed early, suggesting that the formation of the RTC during the first few hours of infection 
is likely due to the acquisition of host cell factors, of which, 51 individual proteins have been 
identified [21].  It is believed that the process of reverse transcription is completed as the RTC 
travels along the cytoskeleton from the distal regions of the cell, to the nucleus.  Once the 
double-stranded viral DNA is complete (the details of reverse transcription will be described 
further in a later section), the RTC becomes integration competent and is then termed the 
preintegration complex (PIC) [22]. 
The lines separating the steps in the virus life cycle between host cell entry and cDNA 
integration are blurred by the inability of researchers to purify the undisturbed RTC from an 
infected cell [23].  As a result, the interdependence of uncoating and reverse transcription 
remains a mystery.  It has recently been shown that reverse transcription can occur in an intact 




In 1975, Howard Temin, David Baltimore, and Renato Dulbecco shared the Nobel Prize for 
Physiology or Medicine for the discovery of the viral enzyme RT. This enzyme is found in a 
variety of virus classes and retrotransposons.  It has also been invaluable to molecular biology by 
allowing the development of new, more sensitive techniques.  HIV-1 RT (Fig. 3) was first 
characterized by Rey et. al.[25] and was found to have various activities including DNA-
dependent DNA polymerization (DDDP), RNA-dependent DNA polymerization (RDDP) and 
ribonuclease H (RNase H) activity.  These studies also found that RT was responsible for 
catalyzing the conversion of RNA to DNA by way of a Mg+ as a divalent cation.  It was later 
discovered that active HIV-1 RT exists as a heterodimer of two subunits, p66 and p51, formed by 
the proteolytic cleavage of a 15 kDa segment of the carboxyl terminus of the p66 subunit [26]. 
The p66 subunit of RT contains three domains: the polymerase, RNase H and connection 
domains [27].  The connection domain (residues 322-440) serves as a bridge between the 
polymerase (restudies 1-321) and RNase H domains (residues 441-560) and plays a key role in 
dimerization of the two subunits [28].  The polymerase domain has three subdomains that 
contribute to the catalytic activity: fingers, palm and thumb.  Between the fingers and thumb, 
along the palm, lies the temple/primer (T/P) binding cleft, which extends through the connection 
and RNase H domains.  The cleft allows the nucleic acid strand to bind to the enzyme and 
exposes the 3’ hydroxyl end of the primer to the catalytic triad (Asp110, 185 and 186), part of 
the highly conserved YMDD motif found in RNA-dependent DNA polymerases.  Binary [29] 
and tertiary [30] structures revealed conformational changes that occur in the enzyme during 
active polymerization.  The thumb domain is known to be flexible and, upon T/P binding, will 
close around the nucleic acid complex through conformational changes.  Binding of a 
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deoxyribonucleic acid triphosphate (dNTP) causes many changes in the structure of RT, 
including rotation of the thumb domain and a clamping motion of the fingers. 
 
 
Figure 3. HIV-1 reverse transcriptase. 
The ternary complex of HIV-1 RT shown is based on the crystal structure 1RTD [30].  The p51 subunit is shown in 
gray.  The polymerase subdomains, fingers (blue), palm (red) and thumb (green), are shown.  The connection 
(yellow) and RNase H (purple) domains of the p66 subunit are also shown.  The double stranded DNA template 
(yellow) and primer (orange) is situated in the binding cleft, and the incoming dNTP (yellow spacefill) is shown in 
the active site.  Residues that make up the polymerase active site are shown in white spacefill (D110, D185 and 
D186)  Image reproduced from a publically available source; http://hivdb.stanford.edu/pages/3DStructures/rt.html 
 
RT requires a T/P to which it will bind with the primer or product site (P-site) of the palm 
subdomain over the 3’-OH group (Fig. 4A), forming the binary complex.  This causes the thumb 
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subdomin to transition from a closed to an open position.  Next, the incoming nucleotide binds in 
the nucleotide binding site (N-site), forming the ternary complex (Fig. 4B).  The final association 
of the dNTP to RT-T/P seems to be a two-step process [31].  During the first interaction 
hydrogen bonds are formed between K65 and the γ–phosphate of the incoming dNTP, between 
R72 and the α–phosphate and β–phosphate, and between Q151 and the sugar 3’-OH [30].  The 
secondary stage requires a conformational change in the enzyme and brings the next correct 
dNTP into proper alignment for catalysis [32].  The α–phosphate of the dNTP and the 3’OH of 
the primer then become properly aligned for nucleophilic attack by the transitioning of the 
fingers from an open to a closed conformation.  This conformational change is the rate-limiting 
step of polymerization and requires complimentarity between the incoming dNTP and the 
template.  The formation of a new phosphodiester bond, facilitated by the presence of Mg+, leads 
to the exclusion of pyrophosphate which exits the active site with the opening of the fingers (Fig. 
4C).  Processive DNA synthesis then requires RT to translocate to position the newly formed 
free 3’OH group in the P-site (Fig. 4D). 
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Figure 4.  Pre- and post-translocation states of HIV-1 RT during processive DNA synthesis. 
A, After association with the T/P, RT positions such that the primer or product site (P-site) contains the last nucleic 
acid added in the nascent DNA chain.  B, The next complementary nucleotide then binds in the nucleotide binding 
site (N-site).  C, Catalysis occurs, forming a new phosphodiester bond and extending the DNA primer by one base.  
At this point, RT is in the pre-translocation state.  Binding of the next complementary nucleotide requires loss of the 
PPi molecule from the product complex.  D, The enzyme must translocate a single position further downstream to 
clear the nucleotide (N) binding site.  This brings the 3’-end of the primer to the P-site referred to as the post-
translocation state. 
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RT-associated RNase H activity 
There are two types of RNase H enzymes and, although they share an overall fold, they differ in 
active site configuration and substrate preference.  RNase H1 (activity found in HIV-1 RT) is 
found in a variety of organisms including prokaryotes and eukaryotes.  It is a non-specific 
endonuclease – in regard to specific nucleotide sequence composition - which catalyzes the 
cleavage of RNA by a hydrolytic mechanism.  All eukaryotic RNase H1 have highly conserved 
regions at their N- and C-termini separated by a variable sequence.  Although the cellular and 
retroviral RNase H enzymes share similar structures and modes of action, their substrate binding 
structure within the active site provides grounds for designing specific inhibitors [33]. 
The HIV-1 RT RNase H active site is composed of four residues (D443, Q478, D498 and 
D549) and the RNase H primer grip, a network of six amino acids (T473, I505, K476, Q475, 
Y501, R448, N474 and Q500), which contact the DNA primer strand and/or the RNA template.  
The active site resides ~18 base pairs upstream of the polymerase active site and is more than 
60Å away in space.  Because it cleaves in such a way that leaves a 3’-OH and a 5’-PO4, the RNA 
strand left annealed to the DNA is able to function as a primer for subsequent DNA synthesis.  
As with the polymerase activity, Mg+ is required for RNase H hydrolysis.  Although there is no 
strict sequence requirement, there does seem to be specificity, possibly with regard to T/P 
secondary structure, RT-T/P interactions and the dimensions of the minor groove [34].  
Additionally, mutational analyses suggest that the residues that contact the primer strand of the 
hybrid through the RNase H primer grip are more valuable than those that contact the template 
itself [35]. 
Several studies have demonstrated interdependence between the polymerase and RNase 
H domains.  Both the polymerase and RNase H domains of the RT molecule contact the T/P 
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simultaneously and both contribute to proper positioning and binding to the nucleic acids [36].  
The polymerase domain is required for efficient substrate binding and cleavage by the RNase H 
domain [37].  Despite this, it is believed that the two activities are not strictly coupled.  The rate 
of polymerization is 7-10 times faster than that of the RNase H domain [31] and RNA molecules 
can be cleaved in the absence of polymerization [38].  Conversely an enzyme with a 
nonfunctional RNase H domain, still has polymerase activity, albeit attenuated [39].  Although it 
is not known whether RT has the ability to simultaneously incorporate dNTPs while cleavage is 
occurring, biochemical studies performed with the inhibitor foscarnet, a pyrophosphate analog, 
suggest that both active sites can be engaged concurrently [40].   
Steps of Reverse Transcription 
Formation of minus strong stop DNA 
Once in the target cell, RDDP is initiated from the 3’-end of the annealed tRNALys3 primer.  Like 
many other polymerases, RT requires a primer for initiation of polymerization.  The tRNA 
anneals to a specific 18-nucleotide sequence within the vRNA termed the primer binding site 
(PBS) and forms a highly structured scaffold for the association of RT [41].  This annealing is 
facilitated in the producer cell by the interaction of NC [42].  Polymerization from this primer 
region towards the 5’-end of the genome generates a DNA intermediate termed minus-strand 
strong-stop DNA (-sssDNA, Fig, 6, step 1).   
First Strand Transfer 
During polymerization, RNase H-mediated degradation of the RNA template from the –sssDNA 
allows it to anneal to the complementary R region on the 3’-end of the RNA genome.  This can 
be an inter- or intramolecular occurrence and is known as the first strand transfer event [43].  It is 
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facilitated by NC protein [44], genome dimerization [45], and RNA secondary structure [46], 
allowing minus strand synthesis to continue from the 3’ end of the genome back to the PBS 
region (Fig. 6, step 2).  The result of this strand transfer event is the formation of the direct 
repeats flanking the genome (long terminal repeats or LTRs). 
There are three different prevailing models to describe the first strand transfer event.  In 
the “forced copy choice” model, a break in the RNA genome induces the transfer to the other co-
packaged RNA molecule based on homology [47].  The “copy choice” model relies on pausing 
or stalling of RT during synthesis as a driving force for template switching [48].  Finally, 
“dynamic copy choice” model dictates that both the polymerase and RNase H activity dictate the 
efficiency of strand transfer [49].  Data supporting this model include the observation that 
decreased dNTP concentrations or mutations in the dNTP binding pocket in RT that decreased 
affinity resulted in a high recombination efficiency.  Additionally, mutations in the RNase H 
domain of RT that decreased cleavage caused a slower rate of template switching.  There are also 
three mechanisms by which strand transfer can occur.  All three rely heavily on the functioning 
of the RNase H domain.  In each case, RNase H cleavage allows removal of the template RNA 
strand to allow for homologous recombination.  An RNase H-deficient RT fails to perform the 
strand transfer reaction, reinforcing the necessity of the function [49].   
Two distinct modes of RNase H cleavage have been described during reverse 
transcription: 3’-end-directed (polymerase-dependent) and 5’-end-directed (a form of 
polymerase-dependent) cleavage.  When the enzyme is bound under polymerization conditions, 
such as during active minus-strand elongation, the polymerase active site is positioned over the 
3’end of the growing DNA strand while RNA hydrolysis is occurring at the opposite end of the 
enzyme in an incomplete and irregular manner based on enzyme pausing and T/P structure (Fig. 
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5A).  It has been observed that as the pausing of RT increases, the RNase H cleavage events 
increase as well.  Because there are 50-100 RT molecules and only two RNA templates to 
process, the excess RT is thought to degrade the remaining bound RNA segments annealed to the 
nascent minus-strand DNA [50].  This occurs through a mode of polymerase-independent 
cleavage where the polymerase active site binds on the DNA opposite the 5’-end of the RNA.  
This positioning results in internal cleavage events ~18 bases away from the 5’-end of the RNA 
(Fig. 5B) which are also dependent on T/P sequence and structure [51].  The RNase H activity of 
RT is also responsible for the precise removal [52-53] of the tRNALys3 and PPT primers during 
reverse transcription.  The final positioning of RT on the T/P is a result of the nature of the T/P 
as well as the cellular milieu (i.e., absence or presence of dNTPS and/or inhibitors) [54].  Some 
have suggested that the main mode of RNase H cleavage during this process is polymerase-
dependent and the polymerase-independent mode plays only a minor role [55].  However, studies 
using an RNase H-deficient RT coupled with Escherichia coli RNase H (supplying the 




Figure 5. Modes of RNase H cleavage during reverse transcription. 
A, During RDDP, RT binds with the polymerase domain (dark blue) positioned over the 3’ end of the growing DNA 
strand (light blue).  This is termed polymerase-dependent or 3’ end directed cleavage.  B, To removed fragments of 
RNA (pink) annealed to the nascent DNA strand after completion of minus strand synthesis, free RT molecules can 
bind with the polymerase domain over the 5’ end of the RNA.  This is termed 5’ end directed cleavage. 
 
Completion of minus strand DNA 
At pausing events during continued minus strand synthesis, the RNA genome is degraded by the 
RNase H activity of the RT.  Two regions, known as the polypurine tract (PPT) and the central 
polypurine tract (cPPT), are protected from this degradation by mispairing of bases.  This allows 
at least a short stretch of RNA to remain annealed to the newly synthesized cDNA to act as a 
primer for plus strand synthesis.  DDDP begins from this point and continues through the 
retained tRNALys3 primer.  
Second Strand Transfer 
After using the tRNA primer as a template for the PBS region of the plus strand, synthesis 
terminates.  At this point, the RNase H of the RT molecule removes the tRNA primer, leaving a 
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short single-strand cDNA complementary to the PBS sequence at the 3’-end of the extended 
minus strand.  RT cleaves the tRNA primer leaving the last two nucleotides behind, allowing for 
efficient integration later.  Using complimentarity and NC, these ends anneal and plus strand 
synthesis resumes, engaging the 3’-end of the newly synthesized minus strand template.  This 
constitutes the second strand transfer event and allows plus strand synthesis to continue in a 
bidirectional fashion (Fig. 6, step 3).  This event is largely intramolecular [43].  Completion of 
integration-competent DNA requires displacement synthesis in order to achieve the full LTRs on 
each end of the viral DNA (Fig. 6, step 4).   
 17 
 
Figure 6. Reverse Transcription. 
Reverse transcription begins from the annealed tRNALys3 primer and RNA-dependent DNA polymerization proceeds 
to the 5’ end of the RNA, generating the minus strand strong-stop DNA intermediate (-sssDNA, step 1).  Once the 
template RNA is degraded, this allows the 5’ end of the nascent DNA to anneal to the 3’ end of the template RNA as 
a result of complementary R regions (first strand transfer event, step 2).  Synthesis proceeds to the 5’ end of the 
RNA while the RNase H activity of the RT incompletely degrades the template strand.  Because of mismatched base 
pairing, the PPT region is saved from degradation and serves as the primer for plus strand synthesis.  RT then begins 
DNA-dependent DNA polymerization towards the 5’ end of the newly formed DNA strand.  Once the tRNALys3 is 
reached, RT removes it, leaving a complementary PBS region which can now bind to the PBS region on the opposite 
end of the DNA strand (second strand transfer event, step 3).  The genome is completed by strand displacement 
synthesis (step 4).  The provirus is then complete and ready for integration (step 5A).  A small percentage of this 
proviral DNA can undergo ligation in the nucleus to form 2-LTR circles (step 5B). 
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1.1.3.3 Integration and Viral Gene Expression 
Integration 
Unlike other retroviruses, HIV-1 does not have to wait for the nuclear envelope to breakdown 
during cell division; the PIC can be imported through the nuclear membrane [20].  In addition to 
its association with microtubules, other components are required for the PIC to traverse the 
nuclear envelope via nuclear import pathways.  The accessory protein Vpr plays a controversial 
role in this process.  Even though it alters the structure of the nuclear lamina in a manner that 
leads to the formation of nuclear herniations that intermittently rupture (presumably allowing 
PIC entry) [57], some studies have shown the nuclear import can occur in arrested cells in its 
absence [58].  MA has also been shown to possibly play a role in nuclear import, as it contains 
two weak nuclear localization signals [59], although the importance of this has been debated 
[60].  It is thought that cellular importins α, β and possibly 7 are required to bind the nuclear 
localization signals present in the PIC and target them to the nucleus by docking the complexes 
to nuclear pore complex proteins and translocating through the pore [61-62].  Additionally, 
fasciculation and elongation protein zeta-1 (FEZ1), Nup98, Nup358, Nup153 and transportin 
3/transportin SR-2 (tnp3) have been shown to be involved in nuclear import [63-65]. 
After nuclear entry, the irreversible process of integration is mediated by IN.  HIV-1 has 
a preference for integration into actively expressed genes [66] however integration in resting T-
cells has been shown to be in suboptimal locations [67].  Host factors have been shown to play a 
role.  For example, integrase binding protein lens epithelium-derived growth factor 
(LEDGF/p75) has been shown to tether the PIC to the host cell’s genome [68].  Additionally, 
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SWI/SNF chromatin-remodeling [69] or DNA-repair [70] complexes and Polycomb-group 
proteins [71] have also been shown to interact with integrase. 
Two reactions are required to integrate the viral DNA into the host genome.  First, IN 
binds to the LTR at each end of the viral DNA and catalyzes the removal of two nucleotides 
from the 3’-end, leaving a C-A with a free 3’-OH group.  This process is known as 
endonucleotide cleavage or 3’-processing.  This can happen in the cytoplasm of the cell, directly 
after the production of cDNA [72].  Next, IN binds to both ends of the viral DNA simultaneously 
with an offset of five base pairs between the two opposite points of insertion.  IN uses that free 
OH group to carry out nucleophilic attacks that result in cuts in the host genome, a process 
known as strand transfer [72].  Finally, the host cell DNA repair enzymes join the viral cDNA 
and cellular genome after extra nucleotides are trimmed from the 5’-end [73] and integration is 
complete (Fig. 2, step 4).    
Viral gene expression. 
The HIV-1 genome contains 9.8 kilobases (kb) of genetic information for the expression of 
nineteen proteins spread out across nine gene sequences.  From 5’ to 3’, the HIV-1 genome 
contains the gag (group-specific antigen), pol (polymerase) and env (envelope) open reading 
frames (ORFs).  Expression of these is regulated by a number of structural components within 
the RNA genome.  Many cis-acting elements, both host- and virus-derived, bind to the proviral 
LTRs which contain the U3, R and U5 regions.  This repeated sequence flanks the functional 
genes of the HIV genome and acts like a viral promoter containing a number of cis-acting 
elements, most found in the 5’ U3 region.  It contains binding sites for cellular factors such as 
nuclear factor kappa B (NFκB), CAT-box enhancer binding proteins, positive transcription 
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elongation factor b (P-TEFb)–cyclin T complex and nuclear factor of activated T cells (NFAT) 
[74], as well as viral factors including Tat and Vpr.   
There are two phases of HIV gene expression.  During the early phase of gene 
expression, the local genome microenvironment is responsible for the level of viral gene 
expression.  Production of Tat, a very potent virus-derived trans-activator, allows the recruitment 
of P-TEFb to the trans-activation response element (TAR), a stem-loop structure present at the 5’ 
end of the RNA.  In the second phase of viral gene expression, the presence of Tat allows for 
hyperphosphorylation and, therefore, activation of RNA polymerase II, which in turn facilitates 
high levels of processive transcription [75]. 
Both full length and subgenomic RNA molecules are produced to serve as genomic RNA 
(to be packaged into nascent virions) and mRNA (to be translated into viral proteins), 
respectively (Fig. 2, step 5).  Fully spliced early transcripts are exported from the nucleus by the 
cellular machinery and translated in the cytoplasm.  Rev, an early protein, is imported into the 
nucleus where it binds to the rev response element (RRE) on unspliced and single-spliced RNA 
(i. e. env, vpu, vif and vpr) to facilitate their export [76].   
The production of viral genes is also regulated at the level of translation through a 
programmed -1 ribosomal frameshift (PRF).  Both Gag (Pr55) and Gag-Pol (Pr160) are 
translated from full-length vRNA (Fig. 2, step 6) using the same start codon but different ORFs 
[77].  The pol ORF is out-of-frame in reference to the gag ORF and, therefore, requires a 
frameshift for translation.  The mechanism is thought to occur as a result of a translocation 
ribosome pausing over a “slippery” site as a consequence of 3’ RNA structure.  When this occurs 
and a frameshift happens, the resulting protein is the full Pr160 polyprotein.  If there is no 
frameshift event, the ribosome encounters a stop codon at the end of the gag gene and produces 
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the Pr55 polyprotein.  In addition to the cis-acting elements in the viral RNA, the frequency of 
the frameshift is also controlled by host translational factors [78].  In this way, the production of 
the 160 kDa polyprotein Gag-Pol is highly regulated and is approximately 5 to 10% of the total 
Gag produced by the PRF [79].    
1.1.3.4 Virus Assembly and Egress 
HIV-1 virus particles can form at the plasma membrane and bud from the surface as immature, 
noninfectious virions (Fig. 2, step 7) or form intracellularly within multivesicular bodies 
(MVBs).  The driving force behind particle assembly is the Gag polyprotein.  Gag is produced 
and co-translationally myristoylated in the cytosol [80].  The N-terminal myristoylation works in 
synergy with the 31 basic amino acids present in the N-terminus of the protein (within the MA 
region) to allow stable association of the Gag molecules with the lipid bilayers of the plasma 
membrane [80].  The newly produced proteins are inserted into the membrane of MVBs and 
trafficked to the plasma membrane through the ESCRT machinery, a pathway important for 
endocytosis in mammalian cells.  The Gag at the surface is found at lipid rafts in the membrane 
which contain high concentrations of cholesterol, glycophingolipids and sphingomyelin [81]   
As the virus buds from the cell, it matures through cleavage of its viral proteins by the 
virally encoded PR (Fig. 2, step 8).  Cleavage is initiated by the dimerization of the Gag-Pol 
polyprotein, which thereby allows autoprocessing of PR to occur in a two-step process.  In the 
initial, rate-limiting step, cleavage of the N-terminus occurs to release the intermediate, which 
has enzymatic activity equivalent to that of the fully mature protein [82].  The second event is the 
subsequent cleavage of the C-terminus to release the mature enzyme [83].  Also arising from the 
processing of the Pol portion of the Gag-Pol polyprotein are RT and IN, which, like PR, are 
required to form dimers for full activity.  Subsequently, Gag is cleaved into three structural 
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proteins, MA, CA, and NC.  Additionally, p2 and p1 spacer proteins are produced from these 
cleavage events in a specific series of cleavage events during maturation, inhibition of which 
renders the virus particles noninfectious [84-85].    
1.2 THERAPEUTIC INTERVENTIONS 
In the absence of an effective vaccine to prevent HIV-1 infection, patients must rely on 
chemotherapeutics to delay the onset of AIDS.  Experiments with 3’-azidothymidine 
(zidovudine, AZT) first demonstrated that HIV-1 infection could be controlled by chemotherapy 
[86-87].  Thanks to the advancement of antiretroviral therapy (ART) during recent years, the 
prognosis for patients infected with HIV-1 has greatly improved.  Because HIV-1 is incurable, 
the inhibitors must be taken for the life of the patient, which requires that the compounds be 
relatively nontoxic and easily administered.  Although HIV-1 relies heavily on the host cell 
machinery for replication, specific steps in the virus life cycle have been targeted for therapeutic 
interventions.  Currently, there are approximately thirty drugs, formulated either individually or 
in combination, available to physicians for the treatment of HIV-1 infected patients [86].  These 
inhibitors span six subclasses and inhibit various stages of the HIV-1 life cycle, including fusion, 
reverse transcription, integration and proteolytic cleavage (maturation).   
1.2.1 Entry 
As previously discussed, the initial step in the viral life cycle is attachment and entry into the 
host cell, which is a multi-step process that provides opportunities for drug development.  In the 
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mid-1990s, CCR5 and CXCR4 co-receptors were identified as essential for HIV-1 entry into the 
CD4+ cell [88-90].  HIV-1-infected individuals with decreased CCR5 co-receptor expression on 
their CD4 cells, due to polymorphisms, had a longer period until disease progression and lower 
viral loads.  Additionally, individuals homozygous for a null mutation on both CCR5 alleles 
appeared to have a strong protection against HIV-1 infection [91].  In light of these observations, 
co-receptor antagonists were developed for use as therapeutics.  There is currently one CCR5 
inhibitor which was approved by the US Food and Drug Administration (FDA) in 2007, 
maraviroc.   
Enfuvirtide, in contrast, is a peptide-based fusion inhibitor which mimics the C-terminal 
domain of the gp41, thereby preventing the formation of the helical hairpin required for fusion of 
the virus envelope with the cellular membrane [92].  Although there is considerable variability in 
the efficacy of this compound against primary HIV-1 strains, a number of next-generation fusion 
inhibitors are being developed [93]. 
1.2.2 Reverse Transcription 
The most heavily targeted step in the virus life cycle is reverse transcription, which comprises 
over 50% of the compounds approved by the US FDA to treat HIV-1 infection.  The two main 
classes of reverse transcriptase inhibitors are NRTIs (Fig. 6A) and NNRTIs (Fig. 6B).  In 
addition, the pyrophosphate (PPi) analog, foscarnet (PFA) also inhibits RT but is rarely used in 
the clinic as a result of toxic side effects and limited bioavailability.  Other RT inhibitors are 
under development, such as those that target RNase H activity, but many of these have limited 
cell uptake ability or result in high toxicity [94].    
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Figure 7. FDA-approved reverse transcriptase inhibitors 
A, Chemical structure of nucleoside reverse transcriptase inhibitors paired with the natural nucleoside they compete 




NRTIs were the first compounds approved by the FDA for the treatment of HIV-1.  Currently, 
there are eight available for treating HIV-infected individuals, although zalcitabine (ddC) is no 
longer used clinically.  As described earlier, these compounds are analogs of naturally occurring 
nucleotides which lack the 3’-OH group required for catalysis during polymerization.  They are 
inactive in their parent form and require the action of host cellular kinases and 
phosphotransferase to form deoxynucleoside triphosphates that can then compete with natural 
nucleotides for binding in the N-site of RT during polymerization [95].  Incorporation of an 
NRTI into the nascent viral DNA chain by RT results in termination of DNA synthesis (Fig 7).  
Many of the compounds approved for HIV-1 therapy were first described as anticancer therapies, 
years before the clinical onset of HIV. 
Although these compounds are analogs of the natural substrate for DNA polymerization, 
there is great diversity in their structures (Fig. 7A).  Two of the eight compounds, didanosine 
(ddI) and ddC, completely lack the 3’-OH group, while compounds such as AZT have a 
substituted azido group at this position.  Two compounds, emtricitabine (FTC) and lamivudine 
(3TC), have a ribose in the L-enantiomer form.  Most of the active, metabolized compounds have 
natural purine or pyrimidine base structures, with the exception of FTC.  Despite their structural 
diversity, these compounds are able to mimic the structural contacts made by natural dNTPs in 
the N-site of the RT during polymerization and therefore can be efficiently incorporated into the 
nascent DNA strand during reverse transcription.  Unfortunately, not all of the NRTIs make good 
substrates for the cellular kinases and require high levels in the bloodstream to be effective HIV 
inhibitors [96].   
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These compounds have their advantages and disadvantage.  Unfortunately, because the 
compounds are designed to mimic the natural dNTP substrate for polymerization, they have a 
significant level of toxicity due to their incorporation during cellular DNA polymerization.  For 
example, AZT is limited by its toxic effects to bone marrow cells, manifested as anemia and 
neutropenia [97].  Mitochondria are particularly sensitive to toxicity because of the 
compartmentalization of nucleoside/nucleotide phosphorylating enzymes and the inability of the 
mitochondrial DNA polymerase γ to distinguish between dNTPs and NRTIs [98-100].  However, 
one major advantage of NRTIs is their intracellular persistence, which allows for more constant 
viral inhibition. 
Zidovudine (AZT) 
AZT was the first inhibitor available to combat HIV-1.  Although it was first described in the 
literature as an anticancer drug in 1964 [101], it was found to inhibit HIV-1 in 1985 [87] and 
approved by the FDA in 1987.  This compound (3’-azido-3’deoxythymidine) contains an azido 
group instead of the 3’-OH.  As a result, polymerization is terminated upon incorporation (Fig. 
7).  This compound selects resistance mutations termed thymidine analog mutations (TAMs) 
which includes M41L, D67N, K70R, L210W, T215F/Y and K219Q/E.  It also selects for 
Q151M which allows RT to discriminate between this compound and the natural dNTP in 
association with A62V, V75I, F77L and F116Y.  Interestingly, HIV-2 does not acquire 
resistance to AZT via TAMs, rather it typically gains the Q151 mutation [102]. 
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Figure 8.  Mechanism of inhibition by zidovudine. 
After phosphorylation by cellular kinases, zidovudine (and other NRTIs) compete with natural dNTPs for incorporation by RT into the growing nascent DNA 
strand.  Once incorporated, polymerization stops due to the lack of 3’-OH group on the NRTI.  In the case of zidovudine, the 3’-OH group has been replaced with 
an azido group. 
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Didanosine (ddI) 
Approved in 1991, ddI (2’, 3’-dideoxyinosine) is metabolized in the host to the active compound 
dideoxyadenosine 5’-triphosphate (ddATP).  Earlier studies investigating 2’,3’-
dideoxyadenosine (ddA) as a potential drug found that it was metabolized into 2,8-
dihydroxyadenosine, a nephrotoxic compound [103].  Additionally, oral administration was not 
an option for the compound because it was degraded by the acidity in the stomach [103].  
Treatment with ddI leads to resistance through the L74V and/or K65R mutations.  Although use 
of this compound has declined, it is still used as an alternative choice for first-line therapy in the 
US and is predominantly used as first-line therapy in the developing world as a result of its low 
manufacturing costs [104]. 
Stavudine (d4T) 
The d4T (2’,3’-didehydro-2’,3’-dideoxythymidine) compound was already described in the 
literature as a potential anticancer agent when it was found to inhibit HIV-1 RT [105].  Although 
it turned out to be less potent than some NRTIs such as AZT, it had a far better safety profile in 
humans and animals [106].  Treatment with d4T selects for TAMs and V75I. 
Tenofovir (TFV) 
Tenofovir (R-9-(2-phosphonomethoxypropyl)adenine) was first described in 1993 [107].  Since 
its approval by the FDA in 2001, its prodrug, tenofovir disoproxil fumarate, has become one of 
the most frequently prescribed RTIs [104].  TNF was also the first inhibitor used in post-




Abacavir, a carbocyclic 2′ -deoxyguanosine nucleoside, was approved by the FDA in 1998.  
Since this time, it has been used to simplify treatment because of its dosing flexibility. Abacavir 
can be prescribed either once daily or twice daily to match the dosing patterns of other regimen 
components, and its availability in fixed-dose combination (FDC) tablets containing lamivudine 
or lamivudine plus zidovudine has allowed regimens with low pill counts.  It is metabolized to 
carbovir triphosphate and competes with dGTP for incorporation in the nascent DNA strand 
[109].  Analyses using peripheral blood mononuclear cells (PBMCs) demonstrated that abacavir 
is significantly more potent then ddI and as effective as AZT [110].  This compound selects for 
combinations of K65R, L74V and M184V. 
Lamivudine (3TC) 
Lamivudine was the first L-nucleoside analogue developed for the treatment of HIV-1  and was 
approved for use in 1995 [111].  It is a highly effective agent that can be dosed once or twice 
daily due to its long intracellular half-life. It also has one of the best tolerability and long-term 
safety profiles among all antiretroviral agents and continues to be preferred as part of initial or 
subsequent combination therapy in HIV-infected patients.  Like FTC, it has the ability to delay 
resistance to AZT or resensitize AZT-experienced patients.  Additionally, like FTC, the 
M184V/I mutations lead to resistance. 
Emtricitabine (FTC) 
Emtricitabine, the (-)-enantiomer of 2′,3′ -dideoxy-5-fluoro-3′-thiacytidine, in combination with 
other inhibitors, is indicated for treatment of HIV-1-infected adults in the US.  Structurally, 
emtricitabine is a fluorinated derivative of lamivudine.  This structural alteration increase the 
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binding affinity for RT and enhances the antiviral activity of emtricitabine relative to that of 
lamivudine [112].  In addition, by decreasing binding affinity for DNA polymerase γ, the 
potential for mitochondrial toxicity was reduced as compared to the original compound [112].  
Because the two compounds are structurally related, FTC-resistant isolates are cross-resistant to 
lamivudine.  Most often the M184V/I mutations are observed, however the K65R mutation also 
reduces susceptibility [113].   
1.2.2.2 NNRTIs 
Although there are NNRTIs at various stages in clinical development, currently there are only 
four approved for use in the United States: efavirenz, nevirapine, delavirdine and etravirine (Fig. 
7B).  Chemically, NNRTIs are small compounds, structurally distinct from NRTIs that do not 
require cellular metabolism.  Functionally, NNRTIs are highly specific allosteric inhibitors of 
HIV-1 RT, which bind to a hydrophobic pocket in the palm domain of the p66 subunit of RT, 
approximately 10Å away from the polymerase catalytic site of the enzyme [27].   
When crystal structures of RT in complex with these inhibitors became available, the 
location and composition of the NNRTI-binding pocket (NNRTI-BP, Fig. 9) was revealed [27, 
114].  It is formed by 16 amino acids from p66 and 2 residues from p51 and, despite a vast array 
of NNRTI chemical structures, crystal structures reveal similar binding for many NNRTIs in the 
pocket.  From these studies, it is known that the binding of NNRTIs cause local distortions in RT 
within the NNRTI-BP as well as long-range alterations in the overall enzyme structure.  The 
pocket is located 10-15Å from the polymerase active site and in both the apo (or unliganded) and 
substrate-bound RT structure, the NNRTI-BP is occluded by the Y181 and Y188 side chains 
indicating that this binding region is closed in the absence of drug [27].  When an NNRTI binds 
to RT, residues Y181 and Y188 in the palm domain rotate and are displaced, creating the 
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NNRTI-BP [115].  The residues which form the walls of the pocket include L100, V109 and 
L234.  The front of the pocket includes K101, K103, P225, P236 and Y318.  More than 30 




Figure 9. HIV-1 RT containing nevirapine bound in the NNRTI-BP. 
The amino acid positions associated with NNRTI resistance that make up the central NNRTI binding pocket are 
shown: L100, K101, K103, V106, V108, V179, Y181, Y188, G190, F227. Additional positions that make up the 
pocket include E138 in the p51 subunit is not pictured.  Residues M230, L234, P236, K238, and L318 form part of 
an extended pocket.  The fingers (blue), palm (red) and thumb (thumb) subdomains are shown.  Also the connection 
(yellow) and RNase H (purple) domains are pictured. (Image reproduced from a publically available source;  
http://hivdb.stanford.edu/pages/3DStructures/rt.html) 
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When DNA is bound to RT, most structural changes occur in the fingers and thumb 
domain, while the primer grip region is stationary.  When an inhibitor is bound (NNRTI), 
significant distortion is noticeable in the catalytic triad as well as the primer grip region, 
suggesting a mechanism of inhibition.  Based on this structural evidence, it has been suggested 
that polymerization is decreased because the highly conserved YMDD motif is altered and the 
primer grip region, responsible for positioning the T/P for catalysis, is perturbed [117].  During 
polymerization in the absence of an inhibitor, the β9-β10 loop which contains the YMDD motif 
flexes and moves downward by 2Å to bind the dNTP and the metal ions [118].  When NNRTIs 
are present, the loop is fixed in the up position, resisting the conformational change [119].  This 
observation has been bolstered by biochemical evidence suggesting that the chemical process of 
phosphodiester bond formation is not slowed by the NNRTI but rather by the rate limiting step of 
conformational change [120].   
Interestingly, it has been demonstrated that some NNRTIs can abrogate initiation from 
the PPT primer under conditions that do not inhibit minus strand elongation and that the binding 
of the drug may cause RT to favor one binding mode over another [121].  Recently, single-
molecule fluorescence resonance energy transfer (FRET) assays have determined that the 
binding of nevirapine causes a destabilization of the RT-T/P complex and leads to enzyme 
reorientation on its substrate, specifically at the PPT region [54, 122].  This could explain why 
NNRTIs preferentially inhibit plus strand synthesis, decrease initiation from the PPT primer, and 
possibly enhance the enzyme’s ability to remove the PPT primer.   
Delavirdine (U-90152, Rescriptor®) 
As with many NNRTIs, this compound exhibits low toxicity, due to its relative lack of inhibition 
of human DNA polymerases [123].  It was first described in the literature in 1993 [123] but is 
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rarely used today as a result of its inconvenient dosing schedule and low potency as compared to 
other NNRTIs such as efavirenz.  It is significantly bulky and protrudes from the binding pocket 
[124].  It forms a hydrogen bond with the lysine at position 103 in the binding pocket and is 
further stabilized through hydrophobic interactions with the proline at position 236.  Therefore, 
the most common resistance mutations seen are K103N and P236L.  Additionally, Y181C is seen 
in therapy, which confers resistance to nearly all NNRTIs. 
Nevirapine (BI-RG-587, Viramune®) 
Nevirapine was first developed in 1990 [125].  Nevirapine in combination with 2 NRTIs is the 
recommended first-line therapy in resource-limited countries.  It is also often used to prevent 
mother-to-child transmission in developing countries, however this has been shown to lead to 
resistance in the mother and affect future treatment outcomes [126].  The most commonly seen 
resistance mutation to nevirapine is Y181C, but substitutions at positions 103, 106, 108, 188 and 
190 are often observed [127].  
Efavirenz (DMP-266, Sustiva™, Stocrin™) 
Efavirenz was first described in the literature in 1995 [128].  Although it is more potent than 
nevirapine or delaviradine, it is considered teratogenic and is contraindicated in women who are 
pregnant or wish to become so [129].  The most commonly selected resistance mutation is 
K103N, but many others were observed during clinical trials [130].  Efavirenz has been shown to 
greatly enhance enzyme heterodimerization, resulting in changes in molecular flexibility, which 
may result in effects on the later stages of viral replication such as premature Gag-Pol processing 
[131-133].  Efavirenz has also been shown to increase homodimerization, which may lead to 
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enhanced processing as a result of increased oligomerizing of the Gag-Pol polyprotein.  
Currently, efavirenz is the most used NNRTI in treatment-naïve patients [134]. 
Etravirine (TMC-125, Intelence™) 
The most recent addition to the list of FDA-approved NNRTIs is etravirine.  It was approved for 
use in 2008 and is known to be active against RTs that have resistance to other currently 
available NNRTIs [135].  This is a result of torsional flexibility in the molecule, which allows for 
various binding conformations within the NNRTI-BP [135].  Resistance can be achieved when 
multiple mutations are present, but the exact resistance profile of etravirine is not known because 
it has not been studied in treatment-naïve individuals. 
1.2.3 Integration 
Raltegravir is a strand transfer inhibitor which blocks the joining of the processed viral DNA 
ends with the host chromosome and was the first of its kind on the market in 2007.  Importantly, 
the compound is active against drug resistant strains of HIV-1 and is considered to be additive or 
synergistic with current treatments [136].  Resistance to this compound has been observed and 
cross-resistance has been noted with investigational integrase inhibitors [137].  An early crystal 
structure of the catalytic core of IN revealed the similarities between it and nucleotidyl strand 
transferases, a recent crystal structure of the prototype foamy virus in complex with viral DNA 
may serve as an appropriate proxy for the study of HIV-1 IN inhibitors [138]. 
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1.2.4 Maturation 
Protease inhibitors were the second class (following NRTIs) to be introduced in the market in 
1995, beginning the era of highly active antiretroviral therapy (HAART), or the therapeutic 
approach to viral inhibition using combinations of inhibitors.  These inhibitors were also the 
product of structure-based drug design which employs the current knowledge of the target 
structure [139].  Currently there are 10 protease inhibitors on the market, all of which are 
competitive inhibitors binding at the active site of protease.  Because they all interact with the 
same hydrophobic pockets on the enzyme, accumulation of only a few resistance mutations can 
lead to resistance to this class of inhibitors [140].    
1.2.5 Combination Therapy 
HIV-1 inhibitors are given in combination for two main reasons: (1) using drug combinations has 
proven to delay the onset of resistance (which will be discussed in a later section) and (2) some 
inhibitor combinations were determined to act in a synergistic fashion.  The success of a 
multidrug regimen in the clinic is dependent not only on pharmacokinetic and pharmacodynamic 
parameters but also on any effect that the compounds may have on each other at the enzymatic 
and cellular levels.  For this reason, a number of studies have focused on the synergy or 
antagonism of drug combinations. 
Synergy was first noted between AZT and ddI [141].  Since this time, a number of studies 
have demonstrated synergy between NRTIs [142-143] as well as NRTIs in combination with 
NNRTIs at the cellular level [144-146].  A mechanism for synergy at the enzyme level between 
NRTIs and NNRTIs has been described.  Excision is one of the two main mechanisms of 
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resistance to NRTIs and will be discussed in detail in a later section (Section 1.3.1.2).  Briefly, 
after the incorporation of a terminating nucleoside, excision allows RT to use cellular ATP to 
perform the reverse reaction and remove the NRTI.  The bound NNRTI negatively affects both 
affinity of ATP for RT and the rate of the chemical step in the excision reaction [147] decreasing 
NRTI removal.  Additionally, synergy can be the result of NNRTI-mediated stable complex 
formation prolonging and enhancing the chain-termination effects of NRTIs possibly as a result 
of the enzyme “flipping” that can occur at the PPT region when NNRTIs are bound [54]. 
Importantly, studies have also determined that some compounds, when given in combination, act 
in an antagonistic fashion.  This is especially true for specific combinations of NRTIs.  For 
example, it has been well described in cell-based and enzyme-based studies that AZT combined 
with d4T is less efficacious than either compound alone.  This is believed to be a result of the 
antagonistic effect that the combination has on the cellular thymidine kinase [148].  This was 
also found to be true in clinical studies where patients responded better to monotherapy than the 
combination of the two [149].  Some treatment combinations also lead to high levels of toxicity.  
For example in initial studies, ddI and d4T demonstrated good antiviral activity and was well 
tolerated.  However, upon further analysis, this combination was associated with a significant 
increased risk of lactic acidosis, peripheral neuropathy, pancreatitis, lipodystrophy, and hepatitis, 
all believed to result from mitochondrial toxicity [150-151]. 
1.2.5.1 Current Recommendations 
Since their inception, NRTIs are considered to be the backbone of HIV-1 therapeutic strategies.  
The current Adult and Adolescent Antiretroviral Treatment Guidelines (published by the US 
Department of Health and Human Services and the International AIDS Society–USA Panel) for 
first-line therapy consists of 2 NRTIs (preferably tenofovir and FTC) in combination with either 
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1) a protease inhibitor (either atazanavir, darunavir, fosamprenavir, or lopinavir) boosted with 
low-does ritonovir, 2) an NNRTI (usually efavirenz) or, more recently, 3) an integrase inhibitor 
[152-153].  To increase adherence and decrease the pill burden for patients, combination 
therapies have been condensed into single pills including; AZT/3TC (Combivir), AZT/ABC/3TC 
(Trizivir), ABC/3TC (Epzicom), TDF/FTC (Truvada) and TDF/FTC/efavirenz (Atripla).  In the 
case of treatment experienced patients, more and more physicians are relying on genotyping to 
determine the best clinical combination.  As will be discussed in the next section, resistance 
mutations that are present in a virus population <1% can affect treatment outcomes [154]. 
1.3 HIV-1 RESISTANCE TO RT INHIBITIORS 
Despite the increased drug availability and decreased mortality rate as a result of fewer infection 
complications, a major hurdle yet to be scaled is antiretroviral resistance.  The development of 
resistant variants is an issue for all HIV-1 inhibitors.  HIV-1 RT is error prone and the errors that 
arise during the viral life cycle, together with the rapid replication of the virus in patients, allow 
the virus to escape the host immune system and develop resistance to antiretroviral drugs.  In the 
milieu of low drug concentrations, which allows low levels of viral replication, drug resistant 
variants are rapidly selected.   
Complete inhibition of viral replication stops the development of resistance.  A 
combination of drugs (usually three) and absolute drug adherence on the part of the patient is 
required to completely block viral replication.  Unfortunately, drug resistance is not only a 
problem for treated HIV+ individuals, but it affects untreated infected and uninfected people as 
well.  The rate of transmission of antiretroviral drug resistant virus has risen during the past 
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decade.  Estimates suggest that 3.4-26% of treatment-naïve patients already have resistance to at 
least one class of inhibitor [155].  Table 1 lists examples of resistance mutations in the 
polymerase and connection domain of HIV-1 RT that confer resistance to NRTIs and NNRTIs 
by different mechanisms. 
 
Table 1. Select clinically relevant drug resistance mutations. 
 
1.3.1 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
There are two main mechanisms for NRTI resistance at the enzyme level: discrimination and 
excision.  By definition, discrimination dictates that RT can acquire mutations which allow it to 
preferentially bind the natural dNTP over the analogue.  With most compounds, usually only one 
residue change is required for this phenomenon.  Discrimination can occur by two mechanisms: 
decreased binding affinity of the compound for the active site of RT (increased KD) or decreased 
Mutation(s) Domain of RT Confers Resistance Mechanism
K65R polymerase ddC, ddI, 3TC, TDF Discrimination; Decreased K pol
K70R polymerase AZT Excision
L74V polymerase ddI, ddC Decreased K pol
K103N polymerase EFV, NEV Increased K D
Q151M polymerase muliple Discrimination
Y181C polymerase NEV Increased K D
M184V/I polymerase 3TC Discrimination; Increased K D
Y318F connection DEL,NEV ?
G333D/E* connection AZT/3TC T/P binding
N348I* connection AZT/NEV Excision; Indirect Effect
A360I/V* connection AZT Excision; Indirect Effect
*indicates that mutation is typically found with other resistance mutations to confer high level 
drug resistance.
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incorporation of the compound into the nascent strand of DNA (decreased kpol).  Mutations that 
allow RT to discriminate include K65R, K70E, L74V, Q151M and M184V.  In the case of 
excision, RT acquires mutations that allow it to remove the chain-terminating nucleoside from 
the end of the primer.  These mutations are collectively referred to as thymidine analog 
mutations or TAMs (because they primarily develop under AZT or d4T drug pressure) and 
include M41L, D67N, K70R, L210W, T215F/Y and K219Q/E. 
1.3.1.1 Discrimination Phenotype 
Discrimination involves the acquisition of one or more mutations that improve the ability of RT 
to discriminate between the natural dNTP and the NRTI-TP.  This typically results in decreased 
catalytic efficiency of NRTI-TP incorporation.  The catalytic efficiency is driven by two factors: 
the affinity of the nucleotide for RT (KD) and the rate of nucleotide incorporation (kpol).  
Typically, discrimination is achieved by the effect of the mutation on one of these two 
parameters. 
Residues in and around the RT polymerase active site dictate resistance as a result of 
their role in polymerization.  The K65 residue resides in the β3-β4 loop of the fingers subdomain 
of RT.  Crystal structures reveal that this residue interacts with the γ–phosphate of the incoming 
dNTP [30].  As a result, the K65R mutation distorts optimal positioning of the NRTI-TP in the 
active site, which reduces the catalytic efficiency of incorporation.  This mutation confers 
resistance to all FDA-approved NRTIs with the exception of AZT [156].  Similarly, molecular 
modeling suggests that residue L74 makes van der Waals contacts with the nucleotide base of the 
incoming dNTP.  The resistance mutation L74V can cause loss of stabilizing interaction that 
leads to a base rotation indirectly affecting the position of the phosphates of the incoming ddNTP 
[157].  This causes resistance to NRTIs such as ddI, ABC and ddC [158]. 
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Discrimination can also occur by steric hindrance (increased KD).  For example, the 
M184V mutation causes high-level resistance to 3TC and FTC.  This residue forms part of the 
highly conserved YMDD motif.  Ternary crystal structures of M184V RT reveal that this residue 
contacts both the dNTP and the 3’-end of the primer terminus and suggests steric hindrance 
between the oxathiolane ring of 3TC-TP and the branched side chain of the reside [29].  This 
affects both the initial binding and the catalysis of the compound resulting in resistance [159].  
Additionally, as a result of this effect, the presence of the M184V mutation causes a decrease in 
viral fitness [160]. 
1.3.1.2 Excision Phenotype. 
The major mechanism of resistance to AZT is excision [161].  This typically requires more than 
one residue change for RT to acquire high levels of resistance.  After the observation that many 
AZT resistance mutations clustered around the dNTP binding pocket, it was demonstrated that 
these mutations increased the rate of phosphorolytic removal of the chain-terminating NRTI 
from the end of the primer, a process termed excision [162-163].  A variety of mutation 
combinations can lead to this phenotype, however they often appear in a distinct order where 
K70R is the earliest and most frequent TAM to arise.  Additionally, RTs harboring these 
mutations tend to be more processive and associate more tightly to the AZT-terminated primer 
[164-165].  These mutations can also confer high-level resistance to ABC, d4T, ddI, ddC and 
TFV [166]. 
The excision reaction is dependent on the terminating NRTI residing in the N-site of the 
RT active site.  The presence of the next correct nucleotide can push RT in an orientation such 
that the NRTI is located in the P-site, in which excision is prevented.  This is referred to as 
“dead-end complex” (DEC) formation because RT is unable to polymerase as a result of the 
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incorporated NRTI and is unable to excise the compound due to its position [167].  Biochemical 
analyses have suggested multiple mechanisms for increased excision as a result of TAMs, 
including increased binding affinity for ATP [168], increased rate of NRTI removal [169], 
decreased sensitivity to DEC formation [162], and a shift in the equilibrium between N- and P-
sites where the N-site is favored [170]. 
A number of factors influence the ability of a terminating nucleoside to be excised, 
including the base structure of the NRTI [171]. Other NRTIs can be excised, albeit not as 
efficiently as AZT-MP.  Some reports suggest that the excision of TFV can be as efficient as 
AZT [172].  Additionally, the azido group is not the primary determining factor for excision.  3’-
azido-ddC, and –ddU are also efficiently removed from the end of a terminated primer by RT 
harboring TAMs.  The removal rates for 3’-azido-ddA and –ddG were greatly reduced as 
compared to the previous [171]. 
The sequence and nature of the template (RNA or DNA) can also influence the efficiency 
of NRTI removal.  Excision and resumption of DNA synthesis occurs with similar rate constants 
on both DNA and RNA, however, the amount of terminating nucleoside removed on the RNA 
template is half what was seen on the DNA template, suggesting that excision on RNA and DNA 
is not equivalent.  Additionally, the RT containing TAMs was unable to excise a terminating 
nucleoside during initiation of minus-strand synthesis [173-174].  This suggests that efficacy of 
TAMs varies during different stages of the production of viral DNAus. 
Additionally, the RNase H domain of RT has recently been suggested to play a role in 
excision.  As described earlier, decreased RNase H activity leads to decreased template 
switching and an increased time period available for nucleoside excision.  This is supported by 
the observation that mutations that decrease RNase H activity also increase resistance to AZT 
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[175].  More specifically, mutations at positions within the RNase H primer grip region were 
shown to increase AZT resistance in the presence of TAMs [176].  
1.3.2 Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
Although NNRTI-based therapy is an attractive therapeutic option based on superior virologic 
outcomes, lower pill burden and less toxicity than the protease inhibitor regimen [177], the low 
genetic barrier to resistance is of concern.  As with the NRTIs, NNRTI resistance emerges as a 
result of many reasons, including non-adherence.  Unlike the other classes of inhibitors 
mentioned, these compounds all bind in the same location, the NNRTI-BP, resulting in a single 
mutation that can lead to reduced susceptibility to the entire class of NNRTIs [178].  Primary 
NNRTI resistance mutations are the most prevalent and their rate in the infected population 
continues to rise [177].  Currently, 6.9% of patients who are screened have at least one NNRTI 
resistance mutation [177]. 
The described mechanism of resistance to NNRTIs results in a loss of interaction 
between the inhibitor and the binding pocket.  Decreased association can occur for a variety of 
reasons, such as a loss of interaction between the compound and the binding pocket or steric 
hindrance [118].  Loss of interaction can happen by alteration of key hydrophobic residues, 
causing a loss of aromatic ring interactions with changes such as Y181C [27].  Steric hindrance 
between the pocket and the compound can also occur with mutations in the central region.  
Alterations at G190 can cause a “bulge” in the pocket, preventing inhibitor association [179].  
Certain changes in the outer rim of the pocket can also prevent drug from entering the pocket.  In 
the case of K103N, an additional network of hydrogen bonds is formed that keeps the NNRTI-
BP closed [180].  Because NNRTIs such as nevirapine and delaviradine have little flexibility in 
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the NNRTI-BP, they make similar side chain interactions and, therefore, cross-resistance occurs.  
Loss of aromatic interaction between the side chains of Y181 and Y188 in RT and some NNRTIs 
is thought to be the main mechanism of resistance [181]. 
The development of novel NNRTIs is underway.  New generation NNRTIs such as 
etravirine (recently approved) and rilpivirine (in late stage clinical trials) do not rely on 
interactions with Y181 and Y188 like the earlier compounds [182].  Instead, because these 
compounds have flexibility between their aromatic rings, they have flexible binding orientations 
in the pocket and have tighter interactions with W229, a residue less prone to mutation [182].  As 
a result, resistance to these second generation NNRTIs requires multiple mutations in the binding 
pocket.  Unfortunately, it has been shown that patients failing first-line therapies infected with 
non-B subtypes may not respond to etravirine [183]. 
1.3.3 Antagonism Between Resistance Mutations 
As mentioned earlier, one of the main reasons RT inhibitors are given in combination is to delay 
the onset of resistant phenotypes.  This phenomenon occurs because many RT inhibitors give 
rise to mutational patterns which are antagonistic.  This has been well described in the case of the 
excision phenotype where mutations such as K65R, L74V and M184V resensitize RT to AZT in 
the presence of TAMs.  For example, AZT/3TC dual therapy gives rise to the M184V mutation 
but delays AZT resistance [184].  Similarly, AZT/ddI dual therapy gives rise to the AZT 
resistance mutation T215Y, but delays the onset of ddI resistance [185].  Additionally, it has 
been demonstrated that the nevirapine resistance mutation, Y181C, can resensitize the virus to 
AZT in the presence of TAMs [186].  This mutation is also associated with reduced ATP-
dependent excision and reduced affinity of the RT-T/P binary complex for ATP [187-188].  The 
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cause of this may be due to an effect on ATP binding to RT and/or a decrease in the overall rate 
of the excision reaction [189-190].  Yet another example of antagonism is the K65R mutation.  
This is a discrimination mutation that confers resistance to various NRTIs including abacavir, 
tenofovir, d4T and ddI.  Although discrimination between AZT and dTTP is increased, K65R 
suppresses the excision phenotype and for this reason it is not found on the same genome as 
TAMs [191-192].  Structurally, this could be a result of decreased flexibility of the fingers loop 
subdomain [193]. 
1.3.4 Resistance Mutations in the Connection Domain 
All NRTI mutations included in the most widely used resistance tables (such as the from the 
International AIDS Society – USA expert panel [194]) map to the DNA polymerase domain of 
HIV-1 RT.  As a result, genotyping has focused on the N-terminal 300 nucleotides of RT, 
encompassing only the polymerase domain.  This standard is a result of mutational clustering 
around the active site and NNRTI-BP.  Most research also focuses on this area as it typically 
correlates with the catalytic activity of the enzyme.  However, strong evidence suggests that 
mutations outside the polymerase domain can affect inhibitor susceptibility.  Kagan and 
colleagues analyzed mutations spanning codons 1-400 (which includes the connect domain) in 
over 40,000 clinical samples [195].  From this analysis, six mutations were identified that 
appeared more frequently in samples from ART-experienced patients as compared to naïve 
patients.  These mutations included N348I, G359S, E370D/G and A371V.  Another study 
performed by Galli and colleagues also examined RT between codons 240 and 400 and  
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compared treatment-naïve and -experienced patients [196].  In this analysis, N348I increased in 
prevalence from less than 1% in treatment-naïve to over 11% in treatment-experienced 
individuals. 
A polymorphism, G333D/E, has been reported in 6% of treatment-naïve patients and 
increases to 12% in individuals having received NRTI therapy [197].  It has been demonstrated 
that this mutation facilitates resistance to both AZT and 3TC in the background of mutations that 
cause a loss of sensitivity to both drug [198].  Interestingly, G333 resides ~35Å from the 
polymerase active site of RT, at the base of the thumb subdomain, which is known to be 
involved in T/P interactions.  Biochemical studies revealed that rather than directly affecting the 
ability of the RT to excise, mutations at residue 333 affect the association of RT and the AZT-
terminated T/P [199].   
In an effort to determine whether mutations in the C-terminal domains of RT confer 
inhibitor resistance, Nikolenko and colleagues performed genotypic and phenotypic analyses 
from 8 treatment-naïve and -experienced patients [200].  This study demonstrated that the C-
terminal regions from the treatment-experienced patients did, in fact, confer AZT resistance 
alone and when paired with TAMs.  In contrast, the same domains from treatment-naïve patients 
did not, reinforcing the role of N-terminal residues in drug resistance.   
1.3.4.1 N348I 
Recently, the N348I mutation was identified which confers resistance to both AZT and NNRTIs 
[201].  It is known to appear early in therapy and is highly associated with TAMs, M184V/I and 
NNRTI resistance mutations K103N, Y181C/I and G190A/S [201-202]. Clinically, this mutation 
has been associated with patients being treated with AZT and nevirapine and has been seen in 
small patient cohorts at a frequency of up to 40% [202] and in larger cohorts at approximately 
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13% frequency [201, 203].  Biochemical analysis of this mutation revealed that increased 
excision was only observed on RNA and not DNA templates [201].  Therefore, it was 
determined that a decrease in RNase H activity led to increased AZT excision.  More 
specifically, it was found that N348I reduces the affinity of RT for the RNA/DNA substrate in 
the RNase H competent complex and increases processive DNA synthesis [204].  By this 
mechanism, the N348I mutation in combination with TAMs can increase the resistance two-fold 
as compared with TAMs alone [201].  However this mutation disappears in the absence of 
chemotherapy, which may be due to its effect on viral replication kinetics [203].   
The location of this mutation in the context of the RT structure does not reveal a 
mechanism by which NNRTI resistance can be achieved (Fig. 10).  The N348 residue lies 27Å 
away from the polymerase active site and 20Å or 60 Å away from the NNRTI binding pocket in 
the p66 or p51 subunits, respectively.  This residue does lie at the base of the thumb domain, 
which may contribute to flexibility and T/P interactions.  The mechanism by which it confers 





Figure 10. Location of N348I in HIV-1 RT complexed with RNA/DNA T/P. 
Crystal structure of RT in complex with the polypurine tract RNA/DNA. The p66 polymerase (blue), connection 
(green) and RNase H domains (yellow) are shown.  The p51 subunit is colored orange.  The DNA and RNA strands 
are in white and purple, respectively.  Residues in the connection and RNase H domain that form part of the nucleic 
acid binding tract are shown in spacefill. 
 
1.3.5 Resistance Mutations in the RNase H Domain 
Mutations in the RNase H domain were proven to decrease the frequency of RT template 
switching, reducing recombination, as well as confer resistance to AZT, d4T and ddI [49, 175].  
Nikolenko and colleagues recently showed that a mutation that decrease RNase H activity 
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increase AZT and d4T resistance alone and in combination with TAMs [175].  From this 
observation it was hypothesized that after incorporation of a chain terminating nucleoside (i. e., 
AZT), there is competition between excision and RNase H activity.  If cleavage of the template 
reduces the T/P hybrid significantly before the terminating nucleoside is removed, excision 
becomes impossible.  Therefore, if RNase H cleavage is decreased, additional time is available 
for the excision reaction.  However, the mutations identified in this study (D549N and H539N) 
have not been observed in clinical samples. 
To identify additional mutations that could contribute to AZT resistance, in vitro 
selection experiments were carried out using increasing concentrations of AZT [205].  These 
studies identified A371V (in the connection domain) and Q509L (in the RNase H domain) that 
confer high-level resistance to AZT in combination with TAMs.  Interestingly, these mutations 
also confer high-level resistance to 3TC and ABC but not d4T and ddI.  Again, these mutations 
have not been identified in clinical samples.  Whether or not codons located beyond the 
polymerase domain should be included in standard genotype testing is under debate [206]. 
 
 49 
2.0  SPECIFIC AIMS 
2.1 BACKGROUND AND PRELIMINARY DATA 
Although it is well known that NNRTIs inhibit polymerization, there is evidence to suggest that 
this is not the main mechanism by which reverse transcription is inhibited.  The work presented 
here is born from observations that IC50 values determined using recombinant RT suggest that 
NNRTIs are less effective inhibitors of in vitro polymerization alone as compared to the overall 
process of reverse transcription in vivo.  Overall, the ability of NNRTIs to inhibit RT or HIV-1 
depends on the assay system used (Table 2).  Recent studies described below suggest that 
NNRTIs may inhibit various stages of reverse transcription.  Cell-free studies designed to 
determine the relationship between RT-mediated polymerization and inhibitors of the reaction 
revealed that inhibition by nevirapine is template length-dependent [207-208].  This suggested 
that slowed catalysis results in fewer full length products for longer templates (in the range of 
186-370 nucleotides).  Despite this, cell-based assays reveal nearly uninhibited levels of -sss 
DNA product in cells infected with virus in the presence of nevirapine (a product of 
approximately 200 nucleotides) [209].  Data presented at the XV International HIV Drug 
Resistance Workshop in 2006 demonstrated that NNRTI-resistant HIV-1 RT is 30-fold more 
resistant to inhibition in strand transfer assays than polymerase or RNase H assays [210], 
indicating that NNRTIs may be more effective during strand transfer.    
To further understand the disconnect between enzyme-based assays and cell-based 
assays, evaluation of the effect of NNRTIs on different functions of RT was necessary.  I began 
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by determining the effect of NNRTIs on the RNase H function (Fig. 11).  Both NNRTIs and 
mutations that confer resistance to these inhibitors have been shown to impact the cleavage rate 
and pattern.  For example, some studies have shown that RNase H cleavage is partially inhibited 
by NNRTIs [125].  However, other groups have shown no effect [211-212] or even enhancement 
of activity [213].  A study investigating various NNRTIs determined that the nature of the 
cleavage (position of RT on the T/P) and the structure of the T/P (primer overhangs) affected the 
outcome of RNase H function assays in the presence of NNRTIs [214].  It was concluded that 
previous conflicting data was generated from different T/P systems.  This study suggested that 
NNRTIs can have enhancing, inhibitory or no effect on the function of RNase H, depending on 
how RT associates with the substrate.  Therefore, NNRTIs can have varied effects on the process 
of reverse transcription depending on the nature of the T/P at each stage. 
 
Figure 11.  HIV-1 RT RNase H cleavage in the presence of efavirenz. 
Audioradiogram of the cleavage activity of WT HIV-1 RT in the absence and presence of increasing concentrations 
of efavirenz.  Fifty nanomolar HIV-1 RT was incubated with varying concentrations of efavirenz, 50 nM TRNA/pr26 
and reaction buffer (Section 3.4.2-3.4.4).  Samples were quenched at 0, 3, 6, 9, 12 and 15 minutes. 
 
More recently, it was shown that there is a correlation between RNase H activity and 
polymerase activity.  It has been previously observed that there is a relationship between the two 
active sites [37, 215-216], but it was only recently demonstrated that decreased RNase H activity 
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could decrease RT template switching during reverse transcription [175].  This study revealed 
that a shift in the equilibrium between the two activities could affect the efficiency of the overall 
reverse transcription process.  The authors also observed a correlation between decreased RNase 
H activity and increased NRTI resistance, suggesting that drug resistance could be affected by 
the interplay between the two active sites.   
Given the known effects of NNRTIs on the function of RT, it is possible that perturbation 
of both the polymerase and RNase H activities, in addition to the effects on the molecular 
dynamics of the enzyme and T/P, may affect other aspects of reverse transcription.  From the 
observation that NNRTIs are more effective in the context of the virus as compared to 
polymerization assays and because NNRTIs have varied effects on RNase H activity, it seems 
that NNRTIs could have effects on steps of reverse transcription which require RNase H 
cleavage, such as strand transfer and primer removal.  Additionally, because a correlation 
between RNase H activity NRTI resistance has been demonstrated [200], it is logical to 
anticipate that inhibitors (or mutations) that affect RNase H activity (i. e. NNRTIs) may affect 
the efficacy of these compounds. 




Table 2. Inhibitory and binding constants determined for NNRTIs using various assay systems 
 
 
Data published a[217], b[218], c[219], d [220], e[221], f[222], g[223], h[224], [222] and [225]. 
Nevirapine Delaviradine Efavirenz
Antivirala (EC50) LAI - P4/R5 -- 85.5 ± 27 63.3 ± 19 1.46 ± 0.29
Antiviralb (EC50) NL4-3 - HeLa-CD4 -- 490 ± 18 290 ± 10 10 ± 0.5
Antiviralc (EC50) HXB2 - MT4 -- 99 ± 32 18 ± 6 1.6 ± 0.8
Antiviralc (EC50) HXB2 - PBMC -- -- -- 2.1 ± 0.5
Polymerased (IC50) -- poly (rC)/oligo (dG) 200 ± 45 5.4 ± 0.4 7.7 ± 0.9
Polymerasee (IC50) -- poly (rA)/oligo (dT) 7222 ± 138 2180 ± 62 94.2 ± 6.3
Polymerasef (IC50) -- heteropolymeric (RNA/DNA) 2217 ± 954 -- 3.9 ± 0.2
RNase H (IC50) -- polymerase-independent 216 ± 40 -- 4.5 ± 0.8
RNase H -- polymerase-dependent Acceleratedb Acceleratedb Acceleratedb
Biacoreg -- -- 1550 ± 441 6.19 ± 0.15 0.63 ± 0.34
EC50 or IC50 or K D (nM)Assay Virus - cell type T/P substrate
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2.2 HYPOTHESIS AND SPECIFIC AIMS 
I hypothesize that NNRTIs block reverse transcription by exerting effects on both the DNA 
polymerase and RNase H active sites of RT, which significantly disrupt the equilibrium between 
these two enzymatic activities. I also hypothesize that the feasibility of NNRTIs to be combined 
with other classes of RT inhibitors in antiretroviral therapies will depend on how these 
compounds respond to the NNRTI-induced shift in the polymerase/RNase H activity 
equilibrium. In this study, I propose to investigate these hypotheses by determining the 
mechanisms by which NNRTIs inhibit RT and by examining the interactions between NNRTIs 
and the nucleoside analog AZT.  These studies will be achieved through two Specific Aims. 
 
In Aim 1, I will determine the molecular mechanism for synergy between the NNRTIs 
and the nucleoside analog AZT and I will investigate the structural changes that occur in RT 
when bound to an NNRTI.  
 
In Aim 2, I will investigate the mechanism(s) by which HIV-1 can evade therapies 
containing combinations containing nevirapine and AZT by determining the molecular 
mechanism(s) by which N348I confers dual resistance. 
 
 54 
3.0  CHAPTER ONE:  EFAVIRENZ ACCELERATES HIV-1 REVERSE 
TRANSCRIPTASE RIBONUCLEASE H CLEAVAGE, LEADING TO DIMINISHED 
ZIDOVUDINE EXCISION 
3.1 PREFACE 
This work was presented at the 14th Annual Conference on Retroviruses and Opportunistic 
Infections. February 25-28, 2007; Los Angeles, California (abstract 490; Radzio J, Sluis-Cremer 
N. Mechanism of Synergy Between Efavirenz and Zidovudine: Role of HIV-1 Reverse 
Transcriptase RNase H Activity.) 
 
Additionally, this chapter was adapted from a published study (Radzio J, Sluis-Cremer N. 
Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to 
diminished zidovudine excision. Molecular Pharmacology 2008 Feb;73(2):601-6), reprinted 
with permission from the American Society for Pharmacology and Experimental Therapeutics. 
 
This work is in partial fulfillment of Specific Aim 1. 
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3.2 ABSTRACT 
Previous biochemical studies have demonstrated that synergy between NNRTIs and NRTIs is 
due to inhibition by the NNRTI of the rate at which HIV-1 RT facilitates ATP-mediated excision 
of NRTIs from chain-terminated T/P. However, these studies did not take into account the 
possible effects of NNRTI on the RNase H activity of RT, despite recent evidence that suggests 
an important role for this activity in the NRTI excision phenotype. Accordingly, in this study, we 
compared the ability of efavirenz to inhibit the incorporation and excision of AZT by HIV-1 RT 
using DNA/DNA and RNA/DNA T/Ps that were identical in sequence. Whereas IC50 values for 
the inhibition of AZT-TP incorporation by efavirenz were essentially similar for both DNA/DNA 
and RNA/DNA T/P, a 19-fold difference in IC50 was observed between the AZT-MP excision 
reactions, the RNA/DNA T/P substrate being significantly more sensitive to inhibition. Analysis 
of the RNase H cleavage events generated during ATP-mediated excision reactions demonstrated 
that efavirenz dramatically increased the rate of appearance of a secondary cleavage product that 
decreased the T/P duplex length to only 10 nucleotides. Studies designed to delineate the 
relationship between T/P duplex length and efficiency of AZT excision demonstrated that RT 
could not efficiently unblock chain-terminated T/P if the RNA/DNA duplex length was less than 
12 nucleotides. Taken together, these results highlight an important role for RNase H activity in 
the NRTI excision phenotype and in the mechanism of synergy between NNRTI and NRTI. 
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3.3 GOAL OF THE STUDY 
Previous studies investigating the effect of NNRTIs on excision were carried out using 
DNA/DNA T/P only and, as such, they ignored the potential contribution of the enzyme's RNase 
H activity in the NRTI excision phenotype. We have recently determined that the polymerase-
dependent RNase H activity of HIV-1 RT can be modulated by the presence of efavirenz (Fig. 
11).  It has not been determined if the same effect is seen on a nucleoside-terminated T/P system.  
Additionally, it has been shown that a balance between nucleotide excision and template RNA 
degradation plays an important role in NRTI resistance [175], therefore, the effect of NNRTIs on 
RNase H activity could contribute to synergy noted between NRTIs and NNRTIs.  To determine 
if the modulation of RNase H activity affects excision, I will compare the ability of RT to excise 
a terminating nucleoside on an RNA and DNA template under equivalent conditions.  
Additionally, I will evaluate the effect of efavirenz on RNase H activity on an AZT-terminated 
T/P system and compare and contrast the ability of NNRTIs to inhibit the ability of RT to 
unblock chain-terminated primers using both RNA/DNA and DNA/DNA T/P substrates. 
3.4 MATERIALS AND METHODS 
3.4.1 Materials 
HIV-1 RT was overexpressed as an N-terminal hexahistidine fusion protein from the prokaryotic 
expression vector p6HRT-PROT [226] and purified to homogeneity as described previously 
[226-227]. Briefly, expression of the recombinant enzyme was induced with 1 mM isopropyl β-
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D-1-thiogalactopyranoside (IPTG) in JM109 strain of E. coli overnight at 30°C.  The cells were 
lysed and the tagged protein was purified using TALON HIS-tag Metal Affinity Resin from 
Clonetech (Mountain View, CA).  Enzyme concentration was determined spectrophotometrically 
at 280 nm using an extinction coefficient (ϵ280) of 260,450 M-1 cm-1.  The activity of the 
enzyme was evaluated using a polymerase activity assay where 25 nM enzyme was incubated in 
reaction buffer [10 mM MgCl2, 50 mM Tris-HCl, pH 7.5 and 50 mM KCl], with 600 nM 
biotinylated oligo (dT) primer (18 nucleotides in length) annealed to poly (rA) (with an average 
length of 600 bases) and 1 μM dTTP containing trace amounts of 3H-labeled dTTP.  The reaction 
was incubated at 37°C for 10 minutes then quenched with 0.25 M EDTA containing SPA 
scintillation beads (Perkin Elmer).  SPA scintillation beads are microspheres containing 
scintillant which are streptavidin conjugated.  When mixed with the reaction, they bind to the 
biotinylated primer and emit light when in the proximity of the incorporated 3H.  The activity 
was quantified using a MicroBeta liquid scintillation counter from Perkin Elmer (Waltham, MA).  
Efavirenz was obtained from the National Institutes of Health AIDS Research and Reference 
Reagent Program. Both RNA and DNA oligonucleotides were synthesized by Integrated DNA 
Technologies (Coralville, IA). The AZT-TP was purchased from Sierra Bioresearch (Tuscon, 
AZ). All other reagents were of the highest quality available and were used without further 
purification.  
3.4.2 Template/Primer Substrates 
All assays were carried out using a 26-nucleotide DNA primer (pr26, 5′ -
CCTGTTCGGGCGCCACTGCTAGAGAT-3′) annealed to either a 35-nucleotide RNA template 
(RNA-T, 5′ -AGAAUGGAAAAUCUCUAGCAGUGGCGCCCGAA CAG-3′) or to a DNA 
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template that was identical in sequence to the RNA template (DNA-T, 5′ -
AGAATGGAAAATCTCTAGCAGTGGCGCCCGAACAG-3′). The pr26 primer was 5′-end 
labeled with [γ-32P]ATP (from Amersham Biosciences) according to the manufacturer’s 
instructions.  For some experiments, the primer was chain-terminated with AZT-monophosphate 
(AZT-MP) to generate pr26-AZT, as described previously [171-172].  Briefly, the pr26 primer 
was annealed to the DNA-T then incubated with wild-type (WT) RT and 100 μM AZT-
tripohosphate (AZT-TP) at 37°C for 30 minutes.  The 32P-labeled chain-terminated primer was 
purified by elution of the appropriate band following resolution by 7 M urea, 16% acrylamide 
denaturing gel electrophoresis. The purified chain-terminated primer was then annealed to the 
appropriate DNA primer for use in phosphorolysis experiments.  Depending on the nature of the 
assay (described below), the 5′ -end of the DNA primer or RNA template was radioactively 
labeled with [γ-32P]ATP (GE Healthcare, Piscataway, NJ).  
3.4.3 Assays for Inhibition of AZT-TP Incorporation and AZT-MP Excision by HIV-1 
RT 
Inhibition of AZT-TP incorporation by efavirenz was determined using a fixed-time assay. In 
brief, 200 nM HIV-1 RT was preincubated with 20 nM T/P (RNA-T/pr26 or DNA-T/pr26) and 
varying concentrations of efavirenz (0-300 nM) in 50 mM Tris-HCl, pH 7.5 and 50 mM KCl at 
37°C for 5 min. Reactions were initiated by the addition of 0.1, 1, or 10 μM AZT-TP and 10 mM 
MgCl2. Reactions were quenched after a defined time (15 s, 1 min, or 15 min) by the addition of 
an equal volume of sample loading buffer (98% deionized formamide, 10 mM EDTA, and 1 
mg/ml each of bromphenol blue and xylene cyanol). Inhibition of AZT-MP excision by efavirenz 
was determined using both fixed-time and time-course assays. In brief, 200 nM HIV-1 RT was 
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preincubated with 20 nM T/P (DNA-T/pr26-AZT or RNA-T/pr26-AZT) in 50 mM Tris-HCl, pH 
7.5, and 50 mM KCl and varying concentrations of efavirenz (0-500 nM) at 37°C for 5 min. 
Reactions were initiated by the addition of 3 mM ATP and 10 mM MgCl2.  Excision reactions 
carried out on the DNA-T/pr26-AZT and RNA-T/pr26-AZT were quenched with an equal 
volume of sample loading buffer after 30, 60, or 90 min, respectively.  Reaction products were 
separated using denaturing polyacrylamide gel electrophoresis and analyzed by densitometry 
using a GS525 Molecular Imager FX (Bio-Rad Laboratories, Hercules, CA).  Data analyses were 
carried-out using SigmaPlot 8.02 and/or SigmaStat 3.00 (Systat Software, Inc., San Jose, CA).  
Statistical significance was determined using the two-sample Student's t test.  The results 
demonstrated that the IC50 values for efavirenz calculated at different AZT-TP concentrations 
(i.e., 0.1, 1.0 or 10 μM), or time points (15 s, 1 min or 15 min), were similar. Likewise, IC50 
values calculated for AZT-MP excision from the fixed time assay (from different time points) or 
time course assays were also similar. Accordingly, for inhibition of AZT-TP incorporation data 
are reported from 1 min assays that contained 1.0 μM AZT-TP, and for inhibition of AZT-MP 
excision data are reported from a fixed time assay that was carried out for 30 min (Figure 12).  
3.4.4 RNase H Assays 
The effect of efavirenz on RNase H activity was evaluated using the RNA-T/pr26-AZT T/P that 
was used in the ATP-mediated excision assays described above. HIV-1 RT (200 nM) was 
preincubated with 20 nM T/P in 50 mM Tris-HCl, pH 7.5, and 50 mM KCl and varying 
concentrations of efavirenz (0 and 150 nM) at 37°C for 5 min.  Reactions were initiated by the 
addition of 3 mM ATP and 10 mM MgCl2.  Aliquots were removed and quenched at varying 
times and analyzed as described above.  
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3.4.5 Gel Mobility Shift Assays 
Gel mobility shift assays were used to evaluate the thermodynamics of RT-T/P interactions. In 
these assays, the amount of T/P-bound RT present in an equilibrium solution was assayed by 
native polyacrylamide gel electrophoresis. RT (0-10 μM total) was equilibrated with 100 nM T/P 
in 50 mM Tris-Cl, pH 7.5, and 50 mM KCl for 15 min as 37°C.  Gels were run at room 
temperature for 30 min (100 V constant voltage) and quantified as described above. 
Discontinuity of sample and gel buffers can cause severe streaking of the bands.  To correct for 
this, the area of the unshifted band was estimated from the lane containing DNA alone, and the 
area between shifted and unshifted bands was counted as the shifted band. The percentage of 
DNA-bound RT was calculated assuming that the amount of DNA in the shifted band 
represented a 1:1 complex of RT-T/P.  
3.5 RESULTS AND DISCUSSION 
This study compared the ability of the NNRTI efavirenz to inhibit HIV-1 RT-catalyzed 
incorporation and excision of the NRTI AZT in reactions carried out on DNA/DNA and 
RNA/DNA T/P that are identical in length and sequence. In this regard, previous detailed 
biochemical studies designed to delineate the molecular mechanism of synergy between NRTIs 
and NNRTIs measured inhibition of NRTI-MP excision on DNA/DNA T/P only [147]. Other 
studies [228-229] evaluated NNRTI-mediated inhibition of NRTI-MP excision on RNA/DNA 
T/P but did not provide a direct comparison with results obtained from complementary 
DNA/DNA T/P. Furthermore, none of these studies considered the possible effects of RNase H 
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activity on the NRTI excision phenotype, despite ample evidence in the literature that this 
activity was modulated by NNRTI binding to RT [213-214, 230-232]. 
3.5.1 Effect of Efavirenz on Excision and Incorporation 
To determine whether efavirenz differentially inhibited the incorporation and/or excision of AZT 
by HIV-1 RT on RNA/DNA and DNA/DNA T/P, IC50 values for these reactions were 
determined (Figure 12E). In all experiments described, the same DNA primer (pr26 or pr26-
AZT) was annealed to DNA or RNA templates (RNA-T or DNA-T) that were identical in length 
and sequence (Figure 12A). The IC50 values for efavirenz inhibition of AZT-TP incorporation by 
HIV-1 RT were calculated to be 19.6 ± 8.5 and 10.2 ± 4.0 nM for the DNA/DNA and 
RNA/DNA T/P, respectively (Figure 12C).  The small difference (∼1.9-fold) between these 
values was found to be statistically nonsignificant.  By contrast, the IC50 values for efavirenz 
inhibition of AZT-MP excision by HIV-1 RT were calculated to be 108.1 ± 32.3 and 5.8 ± 1.1 
nM for the DNA/DNA and RNA/DNA T/P, respectively (Figure 12B and C).  The large (∼19-
fold) difference between these values is statistically significant (p < 0.005). This large difference 
in IC50 value cannot be explained by pre-existing large differences in the rates of AZT-MP 
excision from RNA/DNA or DNA/DNA T/P in the absence of drug (the apparent rates of AZT-
MP excision were calculated to be 0.067 ± 0.005 min-1 and 0.045 ± 0.002 min-1 for DNA/DNA 
and RNA/DNA T/P, respectively) or by differences in apparent affinity of RT for the RNA/DNA 
and DNA/DNA T/P (Figure 12D and 15A). Studies from the Anderson lab [147, 233] and ours 
[120] have demonstrated communication between the NNRTI-binding pocket and the DNA 
polymerase active site in HIV-1 RT, which accounts for the inhibition of RT-catalyzed 
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nucleotide incorporation and excision reactions on a DNA/DNA T/P via a remote effect on the 
chemical step of these reactions. However, the data in Figure 12 suggest that additional 




Figure 12.  Inhibition of RT-mediated AZT-TP incorporation and AZT-MP excision on RNA/DNA 
and DNA/DNA T/P by efavirenz. 
A, Sequences of RNA and DNA templates and DNA primer used in all experiments. In the ATP-mediated excision 
assays, the pr26 primer was chain-terminated with AZT-MP (designated as Z).  B, Representative gel analysis of 
AZT-MP excision reaction carried out on RNA/DNA or DNA/DNA T/P in the absence and presence of varying 
concentrations of efavirenz (0-300 nM).  C, Graph of inhibition of AZT-MP excision by efavirenz on RNA/DNA 
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T/P (○) and DNA/DNA T/P (•) from data in B. IC50 values determined from this isotherm were 11.9 and 100.7 nM 
for the RNA/DNA and DNA/DNA T/P, respectively.  D, HIV-1 RT AZT-MP excision isotherms from RNA/DNA 
T/P (○) and DNA/DNA T/P (•) in the absence of inhibitor. The apparent rates of AZT-MP excision were calculated 
to be 0.067 ± 0.005 min-1 and 0.045 ± 0.002 min-1 for DNA/DNA and RNA/DNA T/P, respectively. The burst 
amplitudes (total amount of product excised at an infinite time point) were 84 and 45% for the DNA/DNA and 
RNA/DNA T/P, respectively. E, IC50 values for the inhibition of AZT-TP incorporation and AZT-MP excision by 
efavirenz under single-turnover conditions. The concentrations of efavirenz used in the incorporation assays were 5, 
10, 20, 30, 50, 100, 150, 250, and 500 nM. The concentrations of efavirenz used in the excision assays were 2, 5, 10, 
30, 50, and 100 nM and 25, 50, 100, 150, 200, and 500 nM for the RNA/DNA and DNA/DNA T/P, respectively. 
The calculated IC50 values for incorporation of AZT-TP were 19.6 ± 8.5 and 10.2 ± 4.0 nM for the DNA/DNA and 
RNA/DNA T/P, respectively. The calculated IC50 values for ATP-mediated excision of AZT-MP were 108.1 ± 32.3 
and 5.8 ± 1.1 nM for the same two substrates, respectively. The difference between these two values was found to be 
statistically significant (p < 0.005). 
3.5.2 Effect of Efavirenz on RNase H Activity 
Recent reports have suggested that the NRTI excision phenotype might also be influenced by the 
RNase H activity of RT [175]. In this regard, several studies have demonstrated that NNRTIs 
modulate the enzyme's RNase H activity. For example, others have shown that this class of drugs 
can accelerate the enzyme's 3′ end -directed (or DNA polymerase-directed) RNase H activity 
[214, 232].  Accordingly, the RNase H cleavage events that occurred during the AZT-MP 
excision reaction were assessed.  It was then delineated whether these affected the efficiency of 
the excision reaction. Figure 13 shows that efavirenz accelerates HIV-1 RT RNase H cleavage, 
data that is consistent with the results of the Shaw-Reid et al. and Hang et al. studies. 
Specifically, efavirenz increased the rate of appearance of a secondary RNase H cleavage event 
that reduced the RNA/DNA duplex length to 10 nucleotides (Figure 13A). It is noteworthy that 
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an inverse relationship between the efficiency of AZT-MP excision and the appearance of this 
secondary RNase H cleavage event was also found in time course assays carried out in the 
absence and presence of efavirenz (Figure 13B and C).  Shaw-Reid et al. further suggested that 
the NNRTI (±)-4-(1-chloro-1,1-difluoromethyl)-4-(2-phenylethynyl)-6-chloro-2H-3,1-
benzoxazin-2-one, an analog of efavirenz, in addition to accelerating the rate of RT RNase H 
activity also altered the specific RNase H cleavage pattern. However, this analysis was based on 
data from a single time point, and our data clearly show that the overall RNase H cleavage 




Figure 13.  Efavirenz accelerates HIV-1 RT RNase H activity. 
A, Autoradiogram of RNase H products generated during ATP-mediated excision assays in the absence and 
presence of efavirenz.  Experiments were carried out as described in Section 3.4.4; the 5′ -end of the RNA template 
is radioactively labeled in these experiments.  The primary RNase H cleavage events occur 17 or 18 nucleotides 
downstream from the polymerase active site.  These cleavages generate RNA/DNA duplex lengths of 19 and 18 
nucleotides, respectively.  B, Isotherm for the rate of appearance of the 19 nucleotide secondary RNase H cleavage 
product generated in the absence (•) or presence (○) of 150 nM efavirenz. The intensity of the 19 nucleotide product 
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was determined by densitometric analyses using Bio-Rad GS525 Molecular Imager FX software and is reported as 
arbitrary units. C, Isotherm for the rate of ATP-mediated AZT-MP excision carried-out by HIV-1 RT in the absence 
(•) or presence (○) of 150 nM efavirenz. 
 
3.5.3 Excision from T/Ps with Decreasing Template Lengths 
To define the relationship between the efficiency of NRTI-MP excision and RNase H activity, I 
next evaluated the ability of HIV-1 RT to excise AZT-MP from a chain-terminated DNA primer 
that was annealed to different RNA templates that were recessed from the 3′ end, therefore 
incrementally decreasing the RNA/DNA duplex length (Figure 14). These data show that the 
efficiency of AZT-MP excision (and AZT-TP incorporation) was severely compromised when 
the RNA/DNA duplex length was decreased to 12 nucleotides or less (Figure 14). If the 
RNA/DNA duplex was reduced to 10 nucleotides - a duplex length consistent with the secondary 
RNase H cleavage event described in Figure 13 - RT was essentially unable to carry-out ATP-
mediated AZT-MP excision.  
3.5.4 Effect of Efavirenz on RT-T/P Association 
Gel mobility shift assays demonstrated that RT exhibited a decrease in affinity for the 
RNA/DNA T/P each time the duplex length was decreased (Figure 15). This decrease in RT-T/P 
affinity provides a plausible explanation for the observed decrease in the efficiency of AZT-MP 
excision (Figure 14).  Taken together, these results provide convincing evidence that the 
sensitivity of the AZT-MP excision reaction on RNA/DNA T/P to efavirenz may be explained by 
the drug-induced accelerated RNase H activity of the enzyme in addition to effects on the 
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chemistry step of the AZT-MP excision reaction. This data also show that AZT-TP incorporation 
is affected by decreasing the RNA/DNA duplex length (Figure 14). However, the rate of AZT-
TP incorporation is significantly faster than the rate of AZT-MP excision, (8.78 s-1 versus 0.54 × 
10-3 s-1; [171] and therefore we would not expect the observed increase in the secondary cleavage 
event that accumulates in a minute time-scale (see Figure 13) to adversely affect the IC50 for 
incorporation of AZT-TP.  
Nikolenko et al. proposed that an equilibrium exists between 1) NRTI incorporation, 
NRTI excision, and resumption of DNA synthesis and 2) degradation of the RNA template by 
RNase H activity that leads to dissociation of the template-primer and abrogation of HIV-1 
replication [175]. In this regard, the authors elegantly showed that mutations in the RNase H 
domain of RT that reduce RT RNase H activity confer AZT resistance. This study lends 
biochemical support to our model and clearly demonstrates that the efficiency of ATP-mediated 
excision reactions on RNA/DNA templates can be influenced by the enzyme's RNase H activity. 
However, the data in Figure 14 show that it is not a decrease in the absolute rate of RNase H 
activity that will contribute to increased NRTI-MP excision, but a decrease in the rate or 
appearance of secondary cleavage events that generate RNA/DNA T/P with duplexes less than 
13 nucleotides. 
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Figure 14. Ability of HIV-1 RT to incorporate or excise AZT on RNA/DNA T/P with decreasing duplex lengths 
Sequences of RNA templates that were annealed to pr26 (for incorporation of AZT-TP) or pr26-AZT (for excision of AZT-MP) are shown. The RNA/DNA 
duplex length is highlighted in bold. Assays were carried out as described in Section 3.4.3. Incorporation and excision activity on the RNA-T template was 




Figure 15. Mobility gel shift assays to assess RT-T/P interactions 
A, representative gel for the binding of RT to RNA-T/pr26-AZT and DNA-T/pr26-AZT. Assays were carried out as 
described in Section 3.4.5. The bound and free T/P substrates are labeled as RT-T/P-AZT and T/P-AZT, 
respectively. The concentrations of RT used in the assay are also indicated. B, plots of RT binding to the RNA/DNA 
T/P substrates with decreasing duplex lengths, as indicated in Figure 14. RNA/DNA T/P with duplex lengths of 26 
nucleotides (•), 18 nucleotides (○), 16 nucleotides ( ▴), 14 nucleotides (▵), 12 nucleotides (▪), 10 nucleotides (□), 8 
nucleotides (♦), and 6 nucleotides (⋄) are shown. 
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4.0  CHAPTER TWO:  EFAVIRENZ ALTERS THE INTERACTION BETWEEN 
HIV-1 REVERSE TRANSCRIPTASE AND TEMPLATE/PRIMER 
4.1 PREFACE 
This work was presented at the XVI International HIV Drug Resistance Workshop, June 12-16, 
2007; Barbados, West Indies.  (abstract published in Radzio J, Sheen C and Sluis-Cremer N.  
Efavirenz Alters the Interaction Between HIV-1 Reverse Transcriptase and Template/Primer. 
Antiviral Therapy 2007; 12 Suppl.2; S133) 
 
The work described in this chapter is in partial fulfillment of Specific Aim 1. 
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4.2 ABSTRACT 
We previously demonstrated that efavirenz exhibits a greater capacity to inhibit HIV-1 RT-
mediated AZT-MP excision from an RNA/DNA T/P than a DNA/DNA T/P (Section 3.0) [225]. 
This was due, in part, to efavirenz increasing the appearance of secondary RNase H cleavage 
products and altering the precise positioning of the T/P.  To gain insight into the mechanism by 
which efavirenz affects RT RNase H activity and T/P binding, I have used fluorescence 
resonance energy transfer (FRET) to measure distances between specific residues in the RNase 
H domain of RT and the 5’-end of the T/P.  Recombinant enzymes that could be modified to 
incorporate AlexaFluor555 (AF555) at two unique sites in the RNase H domain (449 and 560) of 
RT were constructed.  The 5’-ends of the DNA or RNA templates were labeled with 
AlexaFluor647 (AF647).  FRET was determined under equilibrium conditions and analyzed 
according to the Förster theory.  Recombinant enzymes were purified and labeled (~70% 
efficiency) without appreciable loss of RT polymerase or RNase H activity.  Energy transfer 
between the fluorescent donor (AF-555) at residues 449 and 560 in RT and fluorescent acceptor 
(AF647) at the 5’-end of the DNA template was readily measured.  The efficiency of energy 
transfer (E) was calculated to be 0.36 from residue 449 and 0.44 from residue 560.  When 
efavirenz was added to the energy transfer experiments, E decreased to 0.17 from residue 449 
and increased to 0.31 from residue 560. These data provide direct evidence that efavirenz 
binding to RTs alters the precise positioning of the T/P in the DNA binding tract of RT, and I  
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hypothesize that these changes significantly contribute to the mechanism by which efavirenz 
inhibits both nucleotide incorporation and AZT excision and contributes to the observed effect 
on RNase H activity. 
4.3 GOAL OF THE STUDY 
The previous study demonstrated an additional mechanism of synergy between NRTIs and 
NNRTIs.  It was demonstrated that efavirenz exhibits a greater capacity to inhibit HIV-1 RT-
mediated AZT-MP excision from an RNA/DNA T/P than a DNA/DNA T/P (Section 3.0) [225]. 
This was due, in part, to efavirenz increasing the appearance of the enzyme’s secondary RNase 
H cleavage products.  Additionally, it has previously been demonstrated that NNRTIs inhibit 
dNTP incorporation via an indirect effect on the chemistry step of the reaction [120]. 
Despite the wealth of structural information that is available for HIV-1 RT, no structures 
exist in which both NNRTI and the T/P are bound or in which the RNA/DNA hybrid extends 
through both active sites of the enzyme.  Therefore, the effect of the NNRTI on the position of 
the T/P in the binding cleft of RT has not been investigated.  In this regard, I hypothesized that 
the NNRTI affects the efficiency of dNTP incorporation as well as RNase H cleavage by altering 
the precise positioning of the T/P.  Accordingly in this study, I have used FRET to probe RT-T/P 
interactions in the absence and presence of bound NNRTI (i.e. efavirenz).  Determining the 
position of RT on both DNA/DNA and RNA/DNA T/P systems will provide further insight into 
how the bound NNRTI may be modulating RNase H activity and contributing to synergy in the 
absence of a crystal structure. 
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4.4 MATERIALS AND METHODS 
4.4.1 Materials. 
Efavirenz was obtained from the National Institutes of Health AIDS Research and Reference 
Reagent Program. Both RNA and DNA oligonucleotides were synthesized by Integrated DNA 
Technologies (Coralville, IA).  The AZT-TP was purchased from Sierra Bioresearch (Tuscon, 
AZ).  AlexaFluor 555 C5 maleimide conjugate (AF555) was purchased from Molecular Probes 
(Invitrogen, Carlsbad, CA).  All other reagents were of the highest quality available and were 
used without further purification.  
4.4.2 Template/Primer Substrates. 
All assays were carried out using an AlexaFluor-labeled 26-nucleotide DNA primer (pr26-
AF647, 5′ -/AF647/-CCTGTTCGGGCGCCACTGCTAGAGAT-3′) annealed to either a 35-
nucleotide RNA template (RNA-T, 5′ -AGAAUGGAAAAUCUCUAGCAGUGGCGCCCGAA 
CAG-3′) or to a DNA template that was identical in sequence to the RNA template (DNA-T, 5′-
AGAATGGAAAATCTCTAGCAGTGGCGCCCGAACAG-3′). The pr26-AF647 primer was 
chain-terminated with AZT-MP to generate pr26-AF647-AZT, as described previously (Section 
3.4.2).  The 5′ -end of the RNA template was radioactively labeled with [γ-32P]ATP (GE 
Healthcare, Piscataway, NJ) for the RNase H activity evaluation.  
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4.4.3 Generation and Characterization of Labeled Recombinant Mutant Enzymes 
Point mutations were added in the prokaryotic expression vector p6HRT-PROT containing HIV-
1 LAI RT by GenScript (Piscataway, NJ).  Mutations C38V and C280S were inserted in all 
clones to removed naturally occurring cysteine residues.  Mutations E449C and L560C were 
introduced into separate clones to allow labeling of the RNase H domain in specific locations.  
Recombinant RTs were overexpressed as an N-terminal hexahistidine fusion protein and purified 
to homogeneity as described previously (Section 3.4.1). Enzyme concentration was determined 
spectrophotometrically at 280 nm using an extinction coefficient (ϵ280) of 260,450 M-1 cm-1.  
Recombinant RT enzymes containing a cysteine residue at one position were incubated with 
AF555, allowing the formation of a carbon-sulfur bond between the maleimide and the thiol 
group of the cysteine in RT.  RT was incubated over night at 4ºC in a reaction containing 50μM 
RT, 2% dye and reaction buffer (Section 3.4.1).  The labeled RT (RT-AF555) was separated 
from unreacted compound using a NAP-5 column equilibrated with reaction buffer.  A 
polymerase activity assay was used to determine polymerase activity and the previously 
described RNase H assay was used to check that rate and pattern were similar to previously seen 
results (Section 3.4.4). 
4.4.4 FRET Assays 
RT-AF555 (800 nM) was allowed to equilibrate with 1 μM efavirenz in 50 mM Tris-HCl, pH 7.5 
and 50 mM KCl for 5 minutes at 37ºC.  T/P-AF647 (200 nM) was then added and allowed to 
equilibrate with the mixture for an additional 15 minutes.  All data was collected from a 
SpectraMax M2 from Molecular Devices (Sunnyvale, CA) at 37ºC in relative fluorescence units 
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(RFU).  The scan speed for the instrument is 45*K nm/min (K = wavelength interval), readings 
were taken at 1 nm intervals using the photomultipler tube precise setting (Readings: 30), 
excitation wavelength = 502 nm and cutoff wavelength = 550 nm. 
4.4.5 Analysis of Data 
The efficiency of energy transfer (E) is defined as:  
Equation 1 
 
where FDA and FD are the donor fluorescence intensities measured at 570 nm with and without an 
acceptor, respectively, and ƒA is the fractional labeling of the acceptor [234].  Assuming 
fractional labeling to be equivalent, the following equation can be used. 
Equation 2 
 
The distance (r) between donor and acceptor molecules can be determined from the following 
equation:   
Equation 3 
 
where R0 is the critical Förster distance of the donor and acceptor pair at which the FRET 
efficiency is 50%.  R0 for the AF555/AF647 pair is 51Å. 
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4.5 RESULTS AND DISCUSSION 
The effects of NNRTI binding on the association of RT and T/P are unknown due to a lack of 
crystallography data.  There are no crystal structures available for the binary complex of RT with 
a bound NNRTI or RNA/DNA T/P extending through both the polymerase and RNase H active 
sites.  Therefore, it is difficult to anticipate the structural effects which could modulate RNase H 
cleavage in the presence of an NNRTI.  In light of data suggesting that NNRTIs alter template 
cleavage during excision (Section 3.0) I wanted to determine the effects of efavirenz binding on 
the position of the terminated T/P.  To do this in the absence of a crystal structure, I utilized 
FRET. 
4.5.1  Characterization of Labeled RT 
The distance between two fluorophores can be measured by the efficiency of energy transfer 
between them.  By conjugating a donor molecular to RT and an acceptor molecule to the 5’-end 
of the T/P the change is distance between the two can be measured.  To determine the change in 
interaction between the RT and T/P in the presence of an NNRTI, I labeled the RT molecule with 
the maleimide-conjugated AF555 donor at amino acid positions 490 and 560.  Both positions are 
on the superficial layer of the folded enzyme, allowing for energy transfer to the AF647-
conjugated 5’-end of the DNA primer. 
Point mutations were made in the RTs to remove the naturally occurring cysteine 
residues at C38 and C280.  Site-directed mutagenesis was also used to replace the residues at 490 
and 560 to allow addition of the AF555 at specific locations on the enzyme.  The RTs containing 
the mutations and chemical modifications were evaluated for polymerase and RNase H activities 
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to establish that the modifications did not affect the enzyme functionality (Fig. 16).  Previously 
described polymerase activity assays were used to evaluate the polymerase activity of the 
modified enzymes in the absence and presence of efavirenz (Section 3.4.1, Fig. 16A).  The 
polymerase and RNase H activity of the labeled enzymes were not affected by the presence of 
the dyes as determined by comparison to WT enzyme.  Additionally, the NNRTI inhibited the 
polymerase activity of the WT and conjugated enzymes equivalently, decreasing polymerization 
to 5-10% (Fig. 16A).  The appearance of secondary RNase H cleavage products was also 





Figure 16. Characterization of modified recombinant RT function. 
A, DNA polymerase activity of the WT and modified RTs was performed as described using a fixed time point 
activity assay in the absence and presence of 1 μM efavirenz.  B, The RNase H activity of WT and modified RTs 




4.5.2 Effect of NNRTI Binding as Evaluated by FRET Analysis 
FRET is governed by the distance between the donor (AF555) and acceptor (AF647) as well as 
the overlap of the donor emission spectra and the acceptor absorbance spectra.  The spectral 
overlap of the chosen pair (Fig. 17) shows the maximum possible energy transfer between 
AF555 and AF647.  The wavelength at which the donor is most excited does not overlap with the 
excitation spectra of the acceptor and therefore the excitation of the acceptor is generated by the 
emission of the donor.  Accordingly, the chosen donor/accept pair has a high level of maximal 
energy transfer according to their excitation and emission spectra and minimal overlap of 
excitation spectra.   
To determine the changes in association of RT with T/P in the presence of an NNRTI, 
AF-labeled RT was incubated with 1 μM efavirenz, then bound to a terminated AF-labeled T/P, 
containing either a DNA or RNA template.  The donor molecule was excited at 502 nm and the 
energy transferred was measured at 570 nm according to the quenching of the donor (Fig. 18).  
The quenching of the donor molecule is evident by the decrease in emission at 570 nm in the 
presence of the donor-labeled RT and the acceptor-labeled T/P (Fig. 18, yellow shading).  
Conversely, the increase in emission from the acceptor molecule in the presence of the donor-
labeled RT at 670 nm reveals energy transfer (Fig. 18, orange shading).  Using the equations 
shown in Section 4.4.5, the distance between the two dyes was calculated for each set of 
conditions (Table 3).  In each case, with the exception of the 560 residue in the context of the 
DNA template, the distance between the two molecules increased when the NNRTI was present, 
indicating that the RNase H domain and the labeled 5’-end of the primer separated, on both RNA 
and DNA templates, when the NNRTI-BP was formed by the presence of efavirenz. 






Figure 17. Fluorescence spectra for donor dye AlexaFluro555 and acceptor dye AlexaFluor647. 
Donor (AF555, dark green lines) and acceptor (AF647, blue lines) dyes were chosen based on their spectral overlap.  The excitation (dashed lines) and emission 
(solid lines) spectral curves are shown.  The highlighted area under the curve is the spectral overlap representative of energy available for transfer when the donor 




The goal of this study was to use FRET analysis to elucidate how the effect of efavirenz 
on RNase H activity is contributing to synergy between NRTIs and NNRTIs.  My previous data 
showed that NNRTIs enhance the appearance of the 10-nucleotide hybrid product (Fig. 13), a 
template that is not a suitable substrate for the excision reaction (Fig. 14).  In this study, the 
change in distance between the RNase H domain of RT and the 5’-end of the DNA primer were 
measured using FRET.  The data show that the binding of efavirenz causes a shift of RT away 
from the 5’-end of the DNA primer, consistent with the enzyme leaving the polymerase-
competent conformation (Fig. 19).  Recent FRET studies done by Liu, et. al, show that the 
binding of an NNRTI causes increased dynamic motion of RT on the T/P and destabilizes the 
polymerase competent mode of binding [122].  Additionally, recent studies on the RNA/DNA 
T/P equivalent to the PPT RNA primer demonstrated that NNRTIs increase the frequency at 
which the enzyme “flips” and reorients such that the RNase H domain is poised for removal of 
the PPT primer [54].  These FRET data do not demonstrate “flipping,” which reinforces the 
hypothesis that the effect of NNRTIs on the PPT T/P is specific to that structure.  Together, these 
studies demonstrate that NNRTIs are synergistic with NRTIs by two mechanisms:  (1) They can 
accelerate the accumulation of shorted hybrid T/Ps, which are not sufficient substrates for 
excision, and (2) these increased cleavage events may be a result of NNRTIs destabilizing the 
polymerase-competent binding mode, which also decreases DNA polymerization and excision. 
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Figure 18. FRET analysis of RT-AF555 bound to a AF-647 labeled T/P in the absence and presence of 1 μM efavirenz. 
RT (800 nM) was allowed to equilibrate with 1 μM efavirenz in reaction buffer for 5 minutes at 37ºC.  T/P (200 nM of either D NA/DNA, A, or RNA/DNA, B) 
was added and incubated at 37°C for an additional 15 minutes.  All readings were taken at 37ºC.  The highlighted regions represent either the donor quenching 
(yellow) or enhanced acceptor emission (orange).   
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Figure 19. Model depicting effect of efavirenz on T/P association. 
A, Under polymerizing conditions, RT binds such that the polymerase active site (pol domain, dark blue) is 
positioned over the 3’ -end of the DNA primer (light blue).  The AF555 label (green star) in the RNase H domain 
(red) is close to the AF647 on the 5’ end of the primer (blue circle).  This facilitates high energy transfer from one 
dye to the other.  B, When the NNRTI, efavirenz (purple triangle) is bound, the energy transfer is decreased, 
suggesting that RT shifts away from the 5’ end of the primer. 
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5.0  CHAPTER THREE:  N348I REVERSE TRANSCRIPTASE PROVIDES A 
GENETIC PATHWAY FOR HIV-1 TO SELECT TAMS AND MUTATIONS 
ANTAGONISTIC TO TAMS 
5.1 PREFACE 
This work was presented in part at the 16th Annual Conference on Retroviruses and 
Opportunistic Infections February 8-11, 2009, Montreal, Canada (abstract 68; Radzio J, Yap SH, 
Harrigan R, Tachedjian G and Sluis-Cremer N. N348I in HIV-1 Reverse Transcriptase 
Counteracts the Antagonism Between Thymidine Analog Mutations and Y181C) and at the 2nd 
Annual World Summit of Antivirals July 18-25,2009 Beijing, China (abstract; Radzio J and Sluis-
Cremer N. Mechanisms by which N348I in the connection domain of HIV-1 reverse 
transcriptase (RT) confers RT inhibitor resistance). 
 
Additionally, this chapter is adapted from Radzio J, Yap S-H, Tachedjian G, Sluis-Cremer N. 
N348I in Reverse Transcriptase Provides a Genetic Pathway for HIV-1 to Select TAMs and 
Mutations Antagonistic to TAMs.  AIDS 2010 Mar 13;24(5):659-67 reprinted with permission 
from Wolters Kluwer Health. 
 
This work is in partial fulfillment of Specific Aim 2. 
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5.2 ABSTRACT 
Several nonnucleoside (e.g. Y181C) and nucleoside (e.g. L74V, M184V) resistance mutations in 
HIV-1 RT are antagonistic toward TAMs that confer AZT resistance.  The N348I mutation in the 
connection domain of RT also confers AZT resistance, however the mechanisms involved are 
different than those of TAMs. In this study, we examined whether N348I compensates for the 
antagonism of the TAM K70R by Y181C, L74V and M184V.  The efficiency of AZT-MP 
excision and RNase H activity of recombinant purified HIV-1 RT containing combinations of 
K70R and N348I with Y181C, L74V or M184V were assessed using standard biochemical and 
antiviral assays.  As expected, the introduction of the Y181C, L74V or M184V mutations into 
K70R HIV-1 RT significantly diminished the ATP-mediated AZT-MP excision activity of the 
enzyme.  However, the N348I mutation compensated for this antagonism on RNA/DNA T/P by 
significantly decreasing the frequency of secondary RNase H cleavages that reduces the overall 
efficiency of the excision reaction.  The acquisition of N348I in HIV-1 RT - which can occur 
early in therapy, often before TAMs - may provide a simple genetic pathway that allows the 
virus to select both TAMs and mutations that are antagonistic toward TAMs. 
5.3 GOAL OF THE STUDY 
Although the mechanism by which the Y181C mutation antagonizes AZT resistance has been 
described [187-188], it is not known if this mutation also antagonizes the N348I AZT resistance 
phenotype.  Accordingly, in this study my goals were to confirm antagonism of AZT resistance 
at the polymerase active site using recombinant RTs containing the K70R and Y181C mutations.  
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Next, I wanted to analyze the effects of N348I on the AZT-MP excision phenotype in 
combination with the antagonistic mutations.  Finally, I wanted to determine the effect of the 
N348I mutation on RNase H activity in an enzyme harboring the K70R and Y181C mutations. 
5.4 MATERIALS AND METHODS 
5.4.1 Materials 
The K70R, L74V, Y181C, M184V and N348I mutations were introduced into the WT p6HRT-
PROT prokaryotic expression vector using the QuikChange Site Directed Mutagenesis Kit from 
Stratagene (Santa Clara, CA).  Full-length sequencing of mutant RTs was performed to confirm 
the presence of the desired mutations and to exclude adventitious mutations introduced during 
mutagenesis.  The WT, K70R, Y181C, N348I, K70R/Y181C, K70R/Y181C/N348I, 
K70R/L74V, K70R/L74V/N348I, K70R/M184V, K70R/M184V/N348I HIV-1 RTs were 
purified as previously described (Section 3.4.1). The protein concentration of the purified 
enzymes was determined spectrophotometrically at 280 nm using an extinction coefficient (ε 280) 
of 260450 M−1 cm−1, and by Bradford protein assays (Sigma-Aldrich, St. Louis, MO). The 
polymerase activities of the purified WT and mutant enzymes were essentially identical, 
performed as described (Section 3.4.1). The AZT-TP was purchased from Sierra Bioresearch 
(Tuscon, AZ). ATP, dNTPs, and ddNTPs were purchased from GE Healthcare (Piscataway, NJ), 
and [γ-32P]ATP was acquired from PerkinElmer Life Sciences (Boston, MA). RNA and DNA 
oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, IA). 
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5.4.2 Single-Round AZT-MP Excision Assays 
The DNA primer pr26 was 5’-radiolabeled with [γ-32P]ATP and chain-terminated with AZT-MP 
to generate pr26-AZT as reported previously (Chapter 3.4.2). PAZT was then annealed to either a 
35-nucleotide DNA (TDNA: 5’-AGAATGGAAAATCTCTAGCAGTGGCGCCCGAACAG-3’) 
or RNA (TRNA: 5’-AGAAUGGAAAAUCUCUAGCAGUGGCGCCCGAACAG-3’) template. 
ATP-mediated AZT-MP excision assays were carried out by first incubating 20 nM TRNA/pr26-
AZT or TDNA/pr26-AZT with 3 mM ATP, 10 mM MgCl2, 1 µM dTTP and 10 µM ddCTP in a 
buffer containing 50 mM Tris-HCl (pH 7.5) and 50 mM KCl. Reactions were initiated by the 
addition of 200 nM WT or mutant RT. Aliquots were removed at defined times, quenched with 
sample loading buffer (98% deionized formamide, 1 mg/ml each of bromophenol blue and 
xylene cyanol), denatured at 95 °C for 8 min, and then product was resolved from substrate by 
denaturing polyacylamide gel electrophoresis and analyzed as described (Section 3.4.3). 
5.4.3 Assay for RT RNase H Activity 
WT and mutant RT RNase H activity was evaluated using the same AZT-MP chain-terminated 
RNA/DNA T/P substrate described above, except the 5′ -end of the RNA was 32P-end-labeled. 
Assays were carried out using 20 nM TRNA/pr26-AZT, 3 mM ATP and 10 mM MgCl2 in a buffer 
containing 50 mM Tris-HCl (pH 7.5) and 50 mM KCl. Reactions were initiated by the addition 
of 200 nM WT or mutant HIV-1 RT. Aliquots were removed, quenched at varying times, and 
analyzed as described (Section 3.4.3). 
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5.4.4 RT Polymerization Products Formed Under Continuous DNA Polymerization 
Conditions 
Heteropolymeric RNA-dependent or DNA-dependent DNA polymerase T/Ps were prepared as 
reported previously [171, 235].  DNA polymerization reactions were carried out by incubating 
20 nM heteropolymeric T/P complex with 1 µM concentration of each dNTP, 2 µM of AZT-TP, 
3 mM ATP and 10 mM MgCl2 in buffer containing 50 mM Tris-HCl (pH 7.5) and 50 mM KCl. 
Reactions were initiated by the addition of 200 nM WT or mutant RT.  After defined incubation 
periods, aliquots were removed from the reaction tube and quenched with equal volumes of gel 
loading dye.  Products were separated by denaturing gel electrophoresis and quantified. 
5.5 RESULTS AND DISCUSSION 
The Y181C mutation in RT increases HIV-1 sensitivity to AZT even when multiple TAMs are 
co-selected on the same genome [186].  Previous biochemical studies suggested that this 
phenotype was due to the Y181C mutation decreasing the AZT-MP excision activity of both WT 
and D67N/K70R/T215F/K219Q HIV-1 RT by directly impacting ATP binding and/or the rate of 
AZT-MP excision [187-188].  Because the mechanism by which N348I in HIV-1 RT confers 
AZT resistance is different from that conferred by TAMs, I hypothesized that Y181C might not 
antagonize the excision activity of N348I HIV-1 RT and, accordingly, that N348I may 
compensate for the Y181C-mediated antagonism of TAMs.  To investigate this hypothesis, I 
examined the ability of recombinant HIV-1 RT containing combinations of Y181C, K70R and 
N348I to excise AZT-MP using established biochemical assay systems.  In this study, I focused 
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on a single TAM (i.e. K70R) to determine how N348I influenced the interplay between TAMs 
and Y181C at the onset of resistance development.  In this regard, the K70R mutation is one of 
the first TAMs to appear under AZT drug pressure [236].  Furthermore, K70R in HIV-1 RT is 
associated with a strong ATP-mediated excision phenotype in vitro [237]. 
5.5.1 N348I Rescues the Excision Phenotype on RNA Templates        
I first examined the ability of WT, K70R, Y181C, K70R/Y181C, and K70R/Y181C/N348I HIV-
1 RT to excise AZT-MP and rescue DNA synthesis from chain-terminated DNA/DNA and 
RNA/DNA T/Ps (Fig. 20). As described previously, Y181C HIV-1 RT unblocked AZT-MP 
chain-terminated primers inefficiently on both DNA/DNA and RNA/DNA T/Ps (Fig. 20B and 
C). As expected, Y181C also antagonized the ability of K70R RT to excise AZT-MP and recover 
DNA synthesis, although this defect was more pronounced on an RNA/DNA T/P than on a 
DNA/DNA T/P (Fig. 20B and C). Introduction of the N348I mutation into RT containing 
K70R/Y181C RT increased the enzymes excision activity on the RNA/DNA T/P but not on the 
DNA/DNA T/P (Fig. 20B and C). 
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Figure 20. ATP-mediated AZT-MP excision activity of HIV-1 RT on RNA/DNA and DNA/DNA T/Ps 
A, Schematic representation of the ATP-mediated excision assay used in this study.  AZT-MP is designated as “Z”  B, Representative autoradiogram of AZT-MP 
excision reactions carried out by WT and mutant RT on RNA/DNA and DNA/DNA T/Ps. The reaction times were 3, 5, 10, 15, 30, 60 and 90 min.  C, Isotherms 
of ATP-mediated AZT-MP excision reactions carried out by WT and mutant HIV-1 RT on a DNA/DNA T/P (left-hand curve) and on an RNA/DNA T/P (right-
hand curve). Data are the mean ± standard deviation from at least three independent experiments 
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5.5.2 N348I Decreases RNase H Cleavage Alone and When Combine with Antagonistic 
Mutations. 
Our group, as well as those of Drs. Matthias Götte [204] and Vinay Pathak [238], have 
demonstrated that the N348I mutation in HIV-1 RT increases AZT resistance by decreasing the 
frequency of secondary RNase H cleavages that significantly reduce the RNA/DNA duplex 
length of the T/P and diminish the efficiency of AZT-MP excision (Fig. 14).  Previously, I 
delineated the relationship between AZT-MP excision efficiency and RNase H activity on the 
RNA/DNA T/P substrate used in these experiments.  These studies showed that the primary 
polymerase-dependent RNase H cleavage by RT does not impact the AZT-MP excision 
efficiency of the enzyme, but subsequent cleavages that reduce the RNA/DNA duplex length to 
less than 12 nucleotides abolish AZT-MP excision activity (Fig. 14).  In light of these data, I next 
evaluated the RNase H activity of WT and mutant RT that occurred during the ATP-mediated 
excision reactions described in Figure 18.  A schematic of the cleavage positions are depicted in 
Figure 21A.  As reported previously, N348I significantly reduced the frequency of cleavage 
events that decreased the RNA/DNA duplex to 10 nucleotides (Fig. 21B). In comparison with the 
WT enzyme, the K70R and Y181C mutations had minimal impact on the RNase H activity of 
RT (Fig. 21).  Introduction of the N348I mutation into K70R/Y181C RT, however, significantly 
reduced the frequency of this terminal cleavage event (Fig. 21), which is consistent with the 
notion that N348I in HIV-1 RT impacts the efficiency of the AZT-MP excision reaction by 
RNase H-dependent mechanism. 
This study suggests that the acquisition of N348I in HIV-1 RT, which can occur early 
during therapy often before TAMs [201], may provide a simple genetic pathway that allows the 
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virus to select both TAMs and mutations that are antagonistic to TAMs (e.g. L74V, Y181C and 
M184V).  This finding is consistent with recent studies that show a strong association between 
N348I with TAMs, M184V/I and Y181C and that N348I is frequently observed in AZT- and/or 
ddI-containing therapies [203].  In fact, in the Stanford University HIV Database, N348I is 
frequently observed in viruses from patients failing combination antiretroviral therapies that 
contained an NNRTI and either AZT/3TC (frequency of N348I = 22.2%) or AZT/ddI (frequency 
of N348I = 9.5%).  Finally, this study further highlights the complex but potentially important 
role of mutations in the C-terminal domains of HIV-1 RT drug resistance. 
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Figure 21. RNase H cleavage activity of HIV-1 RT that occurs during the AZT-MP excision reaction. 
A, Schematic illustrating the location of the RNase H cleavage sites in the RNA template.  B and C, Representative autoradiogram of the RNase H cleavage 
activity of the WT and mutant HIV-1 RTs.  The reaction times were 1, 3, 5, 10, 20, 30, 45, 60 and 90 min. 
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In the experiments described above, I evaluated the AZT-MP excision and RNase H 
cleavage activities of the WT and mutant enzymes on a defined (in terms of sequence and length) 
RNA/DNA T/P.  Because both excision and RNase H activities of RT are likely affected by 
nucleic acid sequence and length, I next evaluated the ability of WT and mutant enzymes to 
synthesize DNA in the presence of AZT-TP and ATP using a long heteropolymeric RNA 
template, corresponding to the HIV-1 sequence used for –sssDNA synthesis, and primed with a 
DNA oligonucleotide.  The 173- nucleotide incorporation events needed to produce full-length 
DNA product in this assay system allow for multiple AZT-TP incorporation and AZT-MP 
excision events to occur during the formation of full-length final product [171, 235].  In the 
presence of 3 mM ATP, the N348I and K70R enzymes were significantly more efficient than 
WT RT in synthesizing full-length DNA product (Fig. 22).  By contrast, both the Y181C and 
K70R/Y181C enzymes were less efficient in generating full-length DNA product.  Consistent 
with the data in Figure 20, the N348I mutation partially compensated for the antagonism 
between K70R and Y181C: more final DNA synthesis product was observed for the 




Figure 22. Autoradiogram of steady-state DNA synthesis by WT and mutant HIV-1 RT in the 
presence of AZT-TP and 3 mM ATP 
A, Complete autoradiogram indicating primer, final product, and AZT-MP chain-termination sites.  The time points 
for the reactions were 15, 30, 60, 90 and 120 min.  B, Different contrast of the final product bands from the 
autoradiogram presented in (A).  
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Taken together, these data show that the Y181C mutation does not antagonize the ability 
of N348I to excise AZT-MP via an RNase H-dependent mechanism in HIV-1 RT containing 
K70R. Accordingly, N348I in HIV-1 RT compensates for the antagonism between TAMs and 
Y181C. 
5.5.3 N348I in HIV-1 RT Also Compensates for the Antagonism of K70R by L74V and 
M184V 
Previous studies have demonstrated that the NRTI discrimination mutations L74V and M184V 
antagonize the AZT-MP excision phenotype of RT containing TAMs.  To determine whether 
L74V- or M184V-mediated antagonism of TAMs could also be rescued by the N348I mutation, I 
compared the AZT-MP excision and RNase H activities of K70R/L74V HIV-1 RT with 
K70R/L74V/N348I HIV-1 RT and K70R/M184V HIV-1 RT with K70R/M184V/N348I HIV-1 
RT (Fig. 23, Fig. 24).  Consistent with previously published data [189-190, 239], the introduction 
of either the L74V or the M184V mutations into HIV-1 RT containing K70R dramatically 
decreased the ATP-mediated AZT-MP excision activity of HIV-1 RT (Fig. 23). However, the 
N348I mutation partially compensated for the antagonism of K70R by M184V (Fig. 23A) and 
completely alleviated the antagonism of K70R by L74V (Fig. 23B).  As expected, N348I 
decreased the formation of the terminal RNase H cleavage product that reduced the RNA/DNA 




Taken together, these findings demonstrate that neither L74V nor M184V antagonizes the 
ability of N348I in HIV-1 RT to excise AZT-MP via an RNase H-dependent mechanism. 
Therefore, N348I in HIV-1 RT can also compensate for the antagonism of TAMs by L74V and 
M184V. 
 
Figure 23. AZT-MP excision activities of WT and mutant HIV-1 RT on an RNA/DNA T/P. 
A, The autoradiogram shows the AZT-MP excision reactions carried out by K70R/M184V and 
K70R/M184V/N348I HIV-1 RT. The reaction times were 3, 5, 10, 20, 30, 60 and 90 min. The isotherm shows ATP-
mediated AZT-MP excision reactions carried out by WT, K70R, K70R/M184V and K70R/M184V/N348I HIV-1 
RT. B, The autoradiogram shows the AZT-MP excision reactions carried out by K70R/L74V and 
K70R/L74V/N348I HIV-1 RT. The reaction times were 3, 5, 10, 20, 30, 60 and 90 min. The isotherm shows ATP-
mediated AZT-MP excision reactions carried out by WT, K70R, K70R/L74V and K70R/L74V/N348I HIV-1 RT. 
Data are the mean ± standard deviation from at least three independent experiments. 
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Figure 24. RNase H cleavage during ATP-mediated AZT-MP excision by WT and mutant HIV-1 RT. 
A, Representative autoradiogram of the RNase H cleavage activities of K70R/LM184V and K70R/M184V/N348I HIV-1 RT. The reaction times are 1, 3, 5, 10, 
20, 30, 40, 60 and 90 min.  B, Representative autoradiogram of the RNase H cleavage activities of K70R/L74V and K70R/L74V/N348I HIV-1 RT. The reaction 
times are 1, 3, 5, 10, 20, 30, 60 and 90 min.  C, Representative autoradiogram of the RNase H cleavage activities of WT, N348I, Y181C/N348I, L74V/N348I and 
M184V/N348I HIV-1 RT. The reaction times are 1, 3, 5, 10, 20, 30, 60 and 90 min. 
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6.0  CHAPTER FOUR:  SUBUNIT-SPECIFIC MUTATIONAL ANALYSIS OF 
RESIDUE N348 IN HIV-1 REVERSE TRANSCRIPTASE 
6.1 PREFACE 
This work was presented in part at the XVIII International HIV Drug Resistance Workshop. June 
9-12, 2009. Fort Myers, FL (abstract published in Radzio J, Tachedjian G, Sluis-Cremer N. 
Mutational Analysis of Residue Asn348 in HIV-1 Reverse Transcriptase. Antiviral Therapy 
2009; 14 Suppl 2;A32) and at the International HIV and Hepatitis Virus Drug Resistance 
Workshop and Curative Strategies. June 8-12, 2010. Dubrovnik, Croatia (abstract published in 
Radzio J, Sluis-Cremer N. Subunit Specific Mutational Analysis of Residue N348 in HIV-1 
Reverse Transcriptase. Antiviral Therapy 2010; 15 Suppl 2; A79) 
 
This work is in partial fulfillment of Specific Aim 2. 
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6.2 ABSTRACT 
N348I in HIV-1 RT confers both AZT and nevirapine resistance. Several studies have 
demonstrated that the AZT resistance phenotype is due to the decreased appearance of the 
secondary RNase H cleavage products of the N348I mutant RT [201, 204, 240].  The 
mechanism(s) by which N348I in RT confer nevirapine resistance are poorly understood, 
although Nikolenko et al suggest that it also may be related to the enzyme’s RNase H activity 
[241].  Furthermore, it is not clear whether it is N348I in the p66, p51 or both subunits of RT that 
is responsible for the resistance phenotypes.  Here, mutational analyses of residue Asn348 were 
performed to address these questions.  The N348A, N348I, N348L N348E, N348R or N348Q 
mutations were introduced into WT HIV-1 RT.  RTs were purified in which the mutations were 
present in both subunits.  RTs with the N348I, N348A N348E or N348Q mutations in p66 only, 
and one RT with N348L present in p51 only were also purified.  The polymerase and RNase H 
activities of the enzymes, as well as their sensitivities to AZT and nevirapine, were determined 
using appropriate biochemical assays.  For the RTs that harbored mutations in both subunits, it 
was determined that N348I and N348L decreased the enzyme’s RNase H activity and increased 
its capacity to excise AZT-MP, using ATP as a pyrophosphate donor.  In contrast, the N348A 
and N348Q mutations exhibited RNase H and AZT-MP excision activities comparable to WT 
enzyme.  All of the mutant enzymes containing the mutations in both subunits or p51 alsone 
exhibited nevirapine resistance.  The RTs that contained mutations in p66 only, exhibited RNase  
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H activities similar to WT.  In contrast, the RT with N348L in the p51 subunit exhibited 
decreased RNase H activity.  This study suggests that AZT and nevirapine resistance may be due 
to N348I in the p51 but not the p66 subunit of HIV-1 RT.  
6.3 GOAL OF THE STUDY 
Our group has previously demonstrated that the N348I mutation in the connection domain of 
HIV-1 RT confers both AZT and nevirapine resistance [201].  Previous biochemical studies by 
us [201, 240] and others [204, 238] have suggested that N348I confers AZT resistance, in part, 
via an RNase H-dependent mechanism.  Recent biochemical studies have suggested mechanisms 
of nevirpaine resistance conferred by N348I [241-242].  However, these studies fail to 
demonstrate empirical evidence to validate their model and are unable to elucidate which subunit 
is contributing to the resistance phenotype.  Residue N348 in both subunits of HIV-1 RT resides 
distal to the DNA polymerase active site, the RNase H active site, the T/P binding tract and the 
NNRTI-binding pocket (Fig. 10).  Therefore, the structural mechanism by which N348I confers 
dual AZT/nevirapine resistance is not known.  There is no structural data available for RT in a 
binary complex with an RNA/DNA hybrid T/P which extends through the RNase H active site.  
Therefore, the mechanisms by which N348I decreases RT RNase H activity and drug 
susceptibility cannot be inferred.  Furthermore, it is not clear whether it is N348I in the p66, p51 
or both subunits of RT that is responsible for the resistance phenotypes.  However, modeling 
studies performed in our lab suggest that the position of the Asn348 residue in the p51 subunit 
may affect interaction with the RNA/DNA T/P.  The goal of this study was to determine the 
relevance of the N348 residue in the p51 and p66 subunits and determine how it relates to an 
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effect on RNase H activity as well as NNRTI resistance.  The effect of substitutions at Asn348 in 
the p51 subunit was evaluated using modeling studies, followed by biochemical analysis.  
Mutational analyses of residue Asn348 were carried out to specifically address structure-activity-
resistance relationships.  
6.4 MATERIALS AND METHODS 
6.4.1 Materials 
Nevirapine was obtained from the AIDS Research and Reference Reagent Program, National 
Institute for Allergy and Infectious Diseases, National Institutes of Health (NIH).  The AZT-TP 
was purchased from TriLink Biotechnologies. All other nucleotides were purchased from GE 
Healthcare. 
6.4.2 Cloning, Expression and Purification of Recombinant HIV-1 RT 
6.4.2.1 Asn348 Mutations in Both Subunits 
The N348A, N348E, N348I, N348L, N348Q and N348R mutations were introduced into WT 
HIV-1LAI RT in p6HRT-PROT by GenScript (Piscataway, NJ).  Recombinant WT and mutant 
HIV-1 RT was expressed as previously described (Chapter 3.4.1).  All enzymes were found to 
exhibit similar levels of DNA polymerization activity based on activity assays (except for the 
N348R and N348E which were left out of subsequent studies).   
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6.4.2.2 Subunit-Specific Mutagenesis 
RTs in which the N348I, N348A, N348E or N348Q mutations were present in p66 only, and one 
RT in which N348L was present in p51 only were also purified.  Chimeric RTs containing 
mutations in either p51 or p66 were expressed from the pETDuet-1 vector system purchased 
from EMD Biosciences (San Diego, CA).  The WT or mutant p66 subunit was cloned into the 
MCS 1 by PCR from the p6HRT-PROT vector.  Primers used to amplify the full length gene 
contained restriction sites for 5’-end BamH 1 and 3’-end Hind III.  The WT or mutant p51 
subunit was cloned by PCR from p6HRT into the pT7-FLAG-1 expression system purchased 
from Sigma-Aldrich (St. Louis, MO) to acquire the 5’FLAG tag.  The primers used to amplify 
the p51 subunit contained the 5’-Hind III and 3’-Sac I restriction sites.  The 5’-FLAG-p51 was 
then subcloned by PCR from the pT7-FLAG-1 vector into the MCS2 of the pETDuet vector 
containing the p66 subunit.  Primers used to amplify the p51 subunit with the 5’FLAG contained 
the 5’-Nde I and 3’-Avr II restriction sites.  The sequence of the subunits was confirmed using 
vector-specific primers.  The chimeric RTs were expressed in BL21(DE) E coli by induction 
with 1 mM IPTG at 37°C overnight and purified to homogeneity as previously described 
(Chapter 3.4.1).  Polymerization activity was compared using the activity assay previously 
described (Chapter 3.4.1). 
6.4.3 Recombinant Enzyme Characterization 
The sensitivity of the WT and mutant enzymes to nevirapine inhibition was determined using an 
ELISA plate assay.  The template (RNA-T, Chapter 3.4.2) and the pr26 primer (Chapter 3.4.2) 
containing a 5’ end biotin tag used in the assay were purchased from Integrated DNA 
Technologies.  RT (15 nM) was preincubated with various concentrations of nevirapine (0.2 μM-
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10 μM) in reaction buffer for 5 minutes at 37°C.  One micromolar dNTPs (a mixture of dATP, 
dCTP, dGTP and BR-conjugated dUTP) and 200 nM T/P were added and polymerization 
continued for 20 minutes at 37°C.  The reactions were quenched using 0.25 M EDTA and the 
volume of the reaction was transferred to a 96-well streptavidin coated plate.  The plate was 
incubated at room temperature to allow the biotinylated primer to bind to the wells.  The wells 
were washed, 3 times each, with 5.0 M NaOH followed by wash buffer (1x PBS, 0.5% BSA and 
0.2% Tween) to denature and remove the template strand.  An anti-Br HRP-conjugated antibody 
was used to detect the incorporated Br-dUTP and was quantified using chemiluminesence on 
SpectraMax M2 from Molecular Devices.  
6.4.4 Evaluation of RT Polymerization Products Formed Under Continuous DNA 
Polymerization Conditions 
Heteropolymeric RNA/DNA T/P was prepared as described previously (Section 5.4.4).  DNA 
polymerization reactions were carried out by incubating 200 nM WT or mutant RT with 20 nM 
heteropolymeric T/P complex in 50 mM Tris-HCl (pH 8.0) and 50 mM KCl for 5 min before the 
addition of 5 μM of each dNTP, 2.5 μM AZT-TP, 3.0 mM ATP, and 10 mM MgCl2. After 
defined incubation periods, aliquots were removed from the reaction tube and quenched with 
equal volumes of gel loading dye. Products were separated by denaturing gel electrophoresis and 
quantified with a Bio-Rad GS525 Molecular Imager. 
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6.5 RESULTS AND DISCUSSION 
Modeling analyses performed in our lab suggest that mutations at the Asn348 residue in the p51 
subunit may cause alterations in RT which could indirectly effect the association of RT and T/P.  
Recently, a crystal structure of the human RNase H1 was solved in complex with an RNA/DNA 
substrate which extends directly into the enzyme’s active site [33].  Because of the similarity 
between the human RNase H1 and the RNase H domains of HIV-1 RT, the authors were able to 
model an RNA/DNA duplex into HIV-1 RT that extends from the RNase H active site into the 
DNA polymerase active site. In this model, the β14-β15 loop (containing the N348 residue) of 
the p51 subunit of RT directly interacts with the RNA template backbone. Specifically, the 
Y342, P345 and F346 from this loop directly contact the RNA template backbone.  These 
coordinates were then used to model in N348A, N348E, N348I, N348L, N348Q and N348R 
substitutions.  When the N348I mutation is introduced into the p51 subunit in this structure by 
molecular modeling (Fig. 25A), the position of the β14-β15 loop is shifted such that P345 and 
F346 no longer contact the RNA template. This loop distortion appears to be due to the bulky 
size of the isoleucine side-chain because the introduction of an alanine at codon 348 does not 
appear to influence interactions with the RNA template (Fig. 25B).  However, introduction of a 
leucine at this position distorts the loop structure so that only the F346 residue no longer interacts 
with the template. (Fig. 25C).   
To validate this model, mutational analyses of residue Asn348 were performed.  The 
polymerase and RNase H activities of the enzymes, as well as their sensitivities to AZT and 




Figure 25. Molecular models of the β14-β15 loop in the p51 subunit of HIV-1 RT in complex with an 
RNA/DNA duplex that extends into the RNase H active site. 
The WT (green) structure is overlaid with either N348I (A), N348A (B) or N348L (C), shown in pink. The co-
ordinates for this structure were kindly provided by Dr M. Nowotny (NIDDK, NIH). 
 
6.5.1 Comparison of Polymerization Activity. 
The polymerization capacity of each of the enzymes was assessed using the previously described 
activity assay (Section 3.4.1).  The N348A, N348I, N348L and N348Q enzymes harboring 
mutations in both subunits exhibited comparable DNA polymerase activities to WT HIV-1 RT 
(Fig. 26A). By contrast, the N348E and N348R enzymes exhibited significantly diminished 
DNA polymerase activities and, accordingly, were excluded from subsequent analyses.  None of 
the subunit specific mutations decreased RT polymerase activity (Fig. 26B).  Interestingly, the 
N348E mutation produced a functional enzyme when it was present in only the p66 subunit, 
suggesting that it’s affect on the loop position in the p51 subunit causes negative interactions 
with the T/P.  The modeling data show that this substitution caused the loop position to move 




Figure 26. Polymerase activity of Asn348 mutants. 
A, Polymerase activity of Asn348 mutants when the mutation is in both the p66 and p51 subunits (p-value <0.01).  
B, Polymerase activity of Asn348 mutants when the mutation is in the p66 or the p51 subunit. 
 
6.5.2 Evaluation of RNase H activity 
It is known that the N348I mutation present in both subunits decreases the appearance of the 
terminal band which appears during RNase H cleavage using our T/P system (Fig. 24C).  To 
determine if the loop containing this residue modulates this effect, the RNase H activity of the 
recombinant RTs was evaluated as described.  When the mutations were in both subunits, a 
decrease in the appearance of the 10 nucleotide cleavage products relative to the WT was evident 
for the N348I and N348L mutations (Figure 27A).  This observation could be the result of the 
fact that both of these substitutions at the N348 residue cause the β14-β15 loop in the p51 
subunit to move away from the RNA template backbone.  To confirm that it was the mutation in 
the p51 subunit causing this effect, the assay was repeated with the RTs containing subunit-
specific mutations.  The RTs that contained mutations in p66 only (including N348I), exhibited 
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RNase H activities similar to WT.  By contrast, the RT with N348L in the p51 subunit exhibited 
decreased RNase H activity (Fig. 27B).   
Based on this data, the decrease we see in RNase H activity when N348I is present is the 
result of the isoleucine replacement in the the β14-β15 loop in the p51 subunit.  Although I was 
unable to directly test this using an enzyme containing the N348I mutation in the p51 subunit, 
the N348L mutation, which has a similar effect on the position of the loop based on our model, 
decreased the RNase H activity in the p51 subunit.  Interestingly the N348I change causes both 
the P345 and F346 residues to lose contact with the RNA template.  However, the N348L 
substitution allows the P345 residue to maintain contact suggesting that the loss of contact 
between the F346 residue and the RNA template is responsible for the decrease in activity.  As 
discussed earlier, the N348I mutation can allow extended time for excision because the 
RNA/DNA hybrid duplex is maintained for a longer period of time.  
                               110 
 
Figure 27. RNase H cleavage activity of WT and N348 mutant HIV-1 RT. 
A, Autoradiogram of the cleavage activity of WT and N348 mutant HIV-1 RT where the mutation shown is in both RT subunits  B, Autoradiogram of the 
cleavage activity of HIV-1 RT where the subunits were cloned in separate MCS in the pETDuet expression system, allowing the N348 mutations to be expressed 
in each subunit separately. 
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6.5.3 Analysis of RT Polymerization Under Continuous DNA Polymerization Conditions 
in the Presence of AZT-TP 
I analyzed steady-state synthesis by both WT and mutant enzymes in the presence of AZT-TP 
and ATP.  Heteropolymeric RNA template, corresponding to the HIV-1 sequence used for -
sssDNA synthesis, primed with a DNA oligonucleotide was used to confirm that the increased 
excision was a result of the decreased RNase H activity.  The 173- nucleotide incorporation 
events needed to produce full-length DNA product in this assay system allow for multiple AZT-
TP incorporation and AZT-MP excision events during the formation of full-length final product.  
The full length product was separated on a polyacrylamide gel and the data was analyzed by 
phosphoimaging analysis  Figure 28 shows the amount of completed DNA product over time in 
relative density units (RDUs).  For the enzymes harboring the mutations in both subunits, the 
N348I and N348L RTs synthesized significantly greater amounts of full-length DNA as 
compared to the WT or the other mutant enzymes (Fig. 28A).  The efficiency of AZT-MP 
excision can be ordered: N348I RT > N348L RT > N348Q RT > WT RT ≈ N348A RT.   By 
contrast, the enzyme harboring the N348L mutation in the p51 subunit was the only one to 
display high levels of completed product when compared with the other chimeric enzymes (Fig. 
28B).   
As expected, the relative AZT-MP excision activity for each enzyme correlated with its 
RNase H activity, suggesting that the AZT resistance conferred by the N348 residue is an 
indirect result of the decreased RNase H activity.  Previous studies have demonstrated that 
N348I increases the processivity of the enzyme [204].  This could also appear to increase the 
AZT resistance in this assay, although it is not known whether this observation is a result of the 
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mutation in the p66 or p51 subunit.  The N348I substitution in the p66 subunit did not increased 
AZT resistance but it was determine if this enzyme had increased processivity over WT.  
Additionally, studies suggest that this mutation also possesses an RNase H-independent 
mechanism of AZT resistance in similar assays [204].  Again, the AZT resistance assay was not 
performed on a DNA/DNA T/P so this observation cannot be made or correlated with a subunit. 
 
Figure 28. DNA synthesis by WT and mutant HIV-1 RT in the presence of AZT-TP and 3 mM ATP. 
Two hundred nanomolar RT was incubated with 20 nM RNA/DNA T/P, 0.75 μM AZT-TP and 1 μM dNTP in 
reaction buffer.  Aliquots were removed at the indicated times, quenched with formamide and products were 
separated from substrates by gel electrophoresis. Product formation was analyzed by densitometry.  A, Data for 
enzymes containing mutations in both subunits.  B, Data for enzymes containing the subunit-specific mutations. 
6.5.4 Nevirapine Resistance of Recombinant Mutant HIV-1 RTs 
It has been suggested that the nevirapine resistance observed for the N348I mutation is a result of 
the decrease in RNase H activity [241].  To evaluate if a correlation is seen between nevirapine 
resistance and effects on RNase H activity, the NNRTI resistance of the mutant and chimeric 
mutant RTs was evaluated.  Under continuous polymerization conditions, all RTs harboring the 
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mutations in both subunits displayed significant resistance to nevirapine.  Both N348I and 
N348L showed the highest level of resistance at 8- and 11-fold respectively (Fig. 29).  N348A 
and N348Q showed low levels of resistance, 3- and 2-fold, respectively.  Interstingly, none of the 
chimeric RTs containing the mutations in the p66 subunits (including the N348I mutation) 
showed significant nevirpaine resistance.  However, the RT harboring the N348L mutation in the 
p51 subunit demonstrated ~ 6-fold resistance.  This observation suggests that the N348 residue 
confers significant nevirapine resistance in the p51 subunit, but not the p66 subunit.   
 
 
Figure 29. Nevirapine resistance of WT and N348 HIV-1 RTs. 
In this ELISA-based assay, 15nM RT was incubated with 200 nM RNA/DNA T/P and 1 μM dNTPs in reaction 
buffer with increasing concentrations of inhibitor.  Reactions quenched after 20 minutes with 0.25M EDTA and a 
Br-conjugated dNTP was detected using a conjugated antibody.  Statistically significance was based on the WT data 
from each group (* = p-value<0.001, ** = p-value<0.009) 
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This study demonstrates a mechanism of resistance both for AZT as well as nevirapine.  
The inversely correlated decrease in RNase H activity and increase in AZT-MP excision has 
been described [201], but the structural mechanism by which this occurs has been elusive.  In the 
absence of appropriate crystal structures of the binary complex of RT with an RNA/DNA T/P 
passing through both the polymerase and RNase H active sites, it has been impossible to 
determine the structural mechanism influencing the decreased RNase H activity, AZT resistance 
or NNRTI resistance.  However, recent modeling studies in our lab have used related modeling 
based on the human RNase H1 molecule to hypothesize how the isolecuine substitution at 
residue Asn348 could affect the association of RT and T/P [33].  From this analysis, it was 
determined that the Asn348 residue, although not contacting the T/P itself, did reside in a loop 
that may interact with the RNA template.  When this asparagine is replaced with a leucine or 
isoleucine, the loop no longer fully contacts the template.  The goal of this work was to validate 
this model through biochemical analysis.  As the model predicted, the N348L mutation in the 
p51 subunit caused a decreased in RNase H activity, whereas the N348I mutation the p66 subunit 
had no effect on cleavage.   
A recent report by the Pathak group suggested a model for the correlation between RNase 
H activity and NNRTI resistance [241].  In that study, it was demonstrated that in many cases, 
mutations that cause decreased RNase H activity also increase resistance to NNRTIs.  In the 
present study, I also observed an inverse correlation between the decreased in RNase H cleavage 
increased resistance to nevirapine.  However, it is important to note that resistance to the 
NNRTIs is seen in the context of a DNA template as well.  Therefore, in the case of N348I, it is 
not correct to hypothesize that this decrease in sensitivity is purely a result of the effect of these 
mutations on the RNase H activity of the enzyme.   
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7.0  CONCLUSIONS AND FUTURE DIRECTIONS 
7.1 SUMMARY OF PROJECT 
The idea for this project was born from the initial observation that NNRTIs display different 
levels of inhibition depending on the assay system used (Table 2).  Most strikingly, more drug is 
required to inhibit in vitro polymerization by recombinant HIV-1 RT than reverse transcription 
in vivo, suggesting that, in vivo, polymerization is not the only mechanism of inhibition.  This 
raised the question:  in addition to polymerization, are other activities of RT affected by 
NNRTIs?  Although it has been known for years that both NNRTIs and mutations that confer 
resistance to these inhibitors could impact the cleavage rate and pattern, the governing factors of 
this interaction had not been understood.  For example, various studies have shown that RNase H 
cleavage can be inhibited [125], enhanced [213] or remain unaffected [211-212] in the presence 
of NNRTIs.  In order to better understand this modulation, a study was performed using a panel 
of NNRTIs and T/P substrates [214].  This work revealed that inconsistent substrates generated 
conflicting data.  Therefore, the effect of NNRTIs on the RNase H activity of RT is dictated by 
the nature of the T/P. 
The balance between polymerase and RNase H activity has been overlooked for some 
time, likely because little is known about the kinetic interplay of the two active sites.  Because 
processive polymerization is continuous and RNase H activity is periodic, it’s assumed that the 
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rates of the two activities are different and that they are not functioning simultaneously.  
However, recent biochemical studies have shown that locking the 3’-end of the primer at the 
polymerase active site in the ternary complex or with the inhibitor foscarnet produces efficient 
RNase H cleavage demonstrating the RT can engage both active sites [40, 243].  Although it is 
unclear whether or not the two activities are temporally coordinated, this does demonstrate that 
the two are not mutually exclusive. 
The observation that both active sites can simultaneously interact with the T/P suggests 
that the activity or an effect on one could influence the activity of the other despite a distance of 
at least 60 Å between them.  The dependence between the two has been demonstrated 
empirically as well.  Because the binding constant (KD) of the primer grip in the polymerase 
domain is significantly lower than the RNase H domain, mutations in the polymerase T/P grip 
region can affect RNase H activity [244].  Previous studies have shown that alterations in the 
polymerase domain can translate into observable effects in the RNase H domain [37, 215-216] 
In light of these observations, I hypothesized that any compound (or mutation) that has an 
effect on one active site could potentially affect the functioning of the other.  Therefore, the 
therapeutic efficacy of an inhibitor combined with an NNRTI that affects RNase H activity 
would be determined by how that inhibitor reacts to the shift in the polymerase/RNase H 
equilibrium caused by the NNRTI.  The goals of this study were (1) to determine the 
mechanisms of synergy between NRTIs and NNRTIs, including the influence of the nature of the 
template, and (2) to elucidate the mechanisms by which RT can gain resistance to combination 
therapy. 
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7.1.1 Mechanisms of Synergy Between NRTIs and NNRTIs 
There are examples in the literature of synergy between NRTIs and NNRTIs, both in clinical 
studies [245] as well as biochemical analyses [246-248].  The major mechanism proposed in the 
literature is that NNRTIs inhibit ATP-mediated removal of NRTIs from chain-terminated 
primers by negatively affecting both affinity of ATP for RT and the rate of the chemical step in 
the excision reaction, thus sustaining NRTI chain termination [147, 229].  However, these 
studies were carried out using a DNA/DNA T/P only.  In light of the recent evidence 
demonstrating the connection between decreased RNase H activity and increased NRTI excision 
[175], it was postulated that increased RNase H activity could decrease NRTI excision.  As 
discussed, I have previously observed that under certain conditions, NNRTIs can enhance RNase 
H cleavage, possibly contributing to an additional mechanism of synergy (Fig. 3).   
The first goal was to determine if there was in a difference between excision on an RNA 
template as compared to a DNA template in the presence of an NNRTI.  To evaluate this, the 
IC50 value for the inhibition of excision by efavirenz was determined (Fig 12E).  The IC50 for the 
inhibition of excision on the RNA template was much lower than for the DNA template.  
Because the rate of excision on RNA and DNA templates is similar (0.067 ± 0.005 min-1 and 
0.045 ± 0.002 min-1 for DNA/DNA and RNA/DNA T/P, respectively), the data suggest that there 
is an additional factor playing a role in the inhibition of excision on the RNA template.  I next 
evaluated the cleavage pattern in the presence of efavirenz under excision conditions and noticed 
an increase of the 10 nucleotide duplex product as compared to in the absence of inhibitor (Fig 
13).  Because a larger proportion of the T/P was in the 10 nucleotide duplex state during the 
excision reaction, I evaluated the excision on that T/P system.  Figure 14 demonstrates that when 
the T/P duplex is reduced below 12 nucleotides, the excision reaction is inefficient.  Efavirenz 
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accelerates the appearance of the reduced T/P hybrid, and therefore decreases the absolute 
amount of excision that can take place on the substrate.  As a result, efavirenz can decrease 
excision, not only by the increase in KD of ATP as demonstrated by pre-steady state kinetics 
[188], but also by reducing the T/P hybrid length. 
In an effort to elucidate the mechanism by which the NNRTI affect RNase H cleavage, I 
wanted to determine if the presence of the NNRTI affected the association of RT with the T/P.  
Unfortunately, due to the lack of a relevant crystal structures containing RT bound to T/P and an 
NNRTI, the effect of the compound on T/P association has only been speculative.  Additionally, 
it was not known if the nature of the T/P (DNA or RNA) has an effect on this association.  
Accordingly, a FRET system was created to assess the position of the T/P in reference to the 
RNase H domain of RT in the presence of an NNRTI.  RT was pre-bound with a saturating 
concentration of efavirenz and AZT-MP-terminated T/P was added in the absence of magnesium 
to prevent catalysis.  The efficiency of energy transfer from the donor molecule, which was 
covalently attached to the RT molecule, to the acceptor on the 5’-end of the DNA primer was 
measured.   
The distance between the two labeled residues on RT and the 5’-end of the DNA primer 
increased when efavirenz was bound on both the DNA/DNA and RNA/DNA T/P systems (Table 
3).  This suggests that RT binds in a similar fashion, with the RNase H domain moving away in 
space from the 5’-end of the DNA primer, in the presence of efavirenz regardless of the nature of 
the template.  However, the position of the RNase H domain seemed to change more 
dramatically in the context of the RNA template.  Residue 449 moved 7.05Å and residue 560 
moved 4.19Å, creating more distance between the two dyes.  In contrast, on the DNA template, 
residue 449 moved 6.49Å.  The lack of change in the distance between residue 560 and the 5’-
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end of the DNA primer annealed to the DNA template may be the result of a lack of structural 
consistency at this residue as it is located at the end of the C-terminus of the enzyme. 
Since this study, recent work has demonstrated that RT has the ability to “shuttle” on a 
T/P [122].  While the next complimentary dNTP causes RT to favor a polymerase-competent 
mode and stabilize at the 3-end of the DNA primer, the presence of an NNRTI destabilizes the 
structure at the 3’ end increasing “shuttling” [122].  Having less RT bound at the 3’ end for 
polymerization in the presence of NNRTIs constitutes an additional mode of inhibition not 
previously described.  The data shown in Section 4.0 supports this model.  Additionally, 
“flipping” was noted in the presence of an NNRTI on RNA/DNA T/Ps identical to the PPT 
region [54].  This phenomenon did not occur in the T/P system used here, confirming that this 
“flipping” is specific to the PPT region.  Combined with my data, this suggests that the binding 
of the NNRTI allowed RT to move away from the 5’-end of the primer in a polymerase-
incompetent mode.  This motion of RT on the T/P may also explain the increased presence of the 
shorter RNA/DNA hybrids during RNase H cleavage seen in the presence of the NNRTI.  When 
RT is favoring the polymerase-dependent mode, cleavage occurs approximately 18 base pairs 
from the 3’-end of the DNA primer (Fig. 19A).  When the polymerase active site of RT is shifted 
out of this configuration on the T/P, as demonstrated in the presence of an NNRTI, the RNase H 
active site is positioned closer to the 5’-end of the RNA template strand, resulting in smaller 
cleavage products (Fig. 19B).  
Due to the flexibility of the RT enzyme, it is also possible that the RNase H domain alone 
is shifting away from the 5’-end of the primer.  The described experiments do not remove the 
possibility that, although the RNase H domain is lifting away from the DNA primer, the 
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polymerase domain is still positioned at the 3’-end, poised for polymerization.  Additional FRET 
experiments could be done to confirm the location of the N-terminus of the enzyme. 
With the ongoing development of RNase H inhibitors and new NNRTIs, it is important to 
evaluate and understand the mechanism by which combinations of drugs inhibit RT.  RNase H 
activity is an attractive therapeutic target as this activity is absolutely required for virus 
replication.  However, we now know that decreased RNase H activity can facilitate NRTI 
excision therefore, it will be important to evaluate these combinations of classes in vitro and in 
vivo prior to use as therapy.   
7.1.2 Mechanisms by Which HIV-1 RT is able to Circumvent Combination Therapy 
The most powerful tool physicians have to combat the development of resistance to RTIs is 
effective combination therapy.  Selection of inhibitors that work synergistically and give rise to 
antagonistic pathways of resistance delays or prevents rebounding plasma viremia.  
Unfortunately, resistance can arise even in the presence of drug combinations proven to be 
synergistic or that give rise to antagonistic mutational pathways [249-251].  To prevent the 
establishment of multidrug resistance mutations and to develop inhibitors that prevent viral 
replication in the context of current available therapies, it is important to understand how RT can 
overcome different drug combinations.  The work described here further elucidates the 
mechanisms by which HIV-1 RT can develop resistance to combination therapies including 
commonly prescribed NRTIs and NNRTIs.   
The recently described N348I mutation is able to confer resistance to NRTIs and NNRTIs 
by a new mechanism; modulation of RNase H activity [201].  Because this mutation is highly 
correlated with TAMs as well as mutations antagonistic to the excision phenotype, such as 
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L74V, M184V and Y181C [201, 252], I wanted to determine if this mutation allows the 
maintenance of antagonistic combinations.  As previously observed, the excision phenotype 
(conferred by K70R) is antagonized in the presence of Y181C (Fig. 20B and C), M184V (Fig. 
23A) and L74V (Fig. 23B).  When N348I was added, the excision was increased on the RNA 
template in all cases.  N348I was able to recover the excision phenotype on the RNA template, 
suggesting that the RNase H activity may be playing a role in facilitating dual resistance.   
Because N348I confers NRTI resistance by an RNase H-dependent mechanism, I wanted 
to determine if this mutation was affecting the basal level of RNase H activity of the mutants.  
The RNase H activity of the RTs harboring the antagonistic mutations in the absence and 
presence of the N348I mutation was evaluated.  From this analysis it was determined that the 
N348I mutation decreased the RNase H activity of the enzymes both alone (Fig. 21B), in 
combination with K70R, L74V, M184V and Y181C; (Fig. 21C) and in the presence of K70R 
paired with L74V (Fig. 24B), M184V (Fig. 24C) and Y181C (Fig. 21B).  These observations 
support previous data suggesting that N348I increases AZT-MP excision by an RNase H-
dependent mechanism [201].  This data also suggests that N348I can compensate for antagonism 
of the excision phenotype by the same mechanism.  Additionally, the increased RNase H activity 
of Y181C alone (Fig. 21B) suggests an added mechanism of antagonism between the K70R and 
Y181C mutations. 
Finally, I determined the effect of the N348I mutation in combination with the mutations 
correlated with multiple rounds of incorporation and excision, using a biologically relevant, 
heteropolymeric RNA/DNA T/P system.  This experiment demonstrates how each set of 
mutations functions during –sssDNA synthesis in the presence of AZT-TP during reverse 
transcription.  N348I had the greatest amount of completed product (Fig 22).  Previous studies 
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have demonstrated that N348I can compensate for a decrease in processive DNA synthesis 
caused by TAMs [204] that, paired with RNase H-mediated increased AZT-MP excision, allows 
the formation of more product.  N348I affects RNase H activity causing an indirect effect which 
circumvents the antagonism.  In this case, the biochemical antagonism is still present, but the 
N348I mutation can overcome this by extending the time for excision. 
Despite the data showing the effects of the N348I mutation in biochemical assays, the 
lack of structural data hindered our understanding of the structural characteristics which could 
lead to the resistant phenotype.  In an effort to understand how N348I was modulating RNase H 
activity, we used a model of RT complexed with an RNA/DNA template primer based on the 
crystal structure of the human RNase H1.  In this structure, the N348 residue resides on a β loop 
that contacts the RNA template (Fig. 25).  When N348I is substituted at this position, the loop 
moves away from the template, suggesting a mechanism of RNase H modulation. 
To validate the hypothesis that the isoleucine substitution was decreasing RNase H 
activity through the effect in the p51 subunit, I characterized RTs containing various mutations at 
the Asn348 residue in both subunits and each subunit individually.  When the leucine and 
isoleucine residues at 348 were present in both subunits, a decrease was noted in RNase H 
activity (Fig. 27A).  This translated into increased AZT-MP excision on the heteropolymeric 
RNA/DNA T/P (Fig. 28A).  Interestingly, these RTs also conferred the highest level of NNRTI 
resistance (Fig. 29, purple bars).  However, the level of resistance seen when the N348L 
mutation was in the p51 subunit does not explain the 11-fold resistance when the mutation is in 
both subunits.  This demonstrates that the highest level of nevirapine resistance is achieved when 
the mutation is in both subunits.  When the N348I mutation was in the p66 subunit only, the 
RNase H activity (Fig. 27B) and AZT-MP excision (Fig. 28B) were similar to that of WT.  The 
 123 
mutation also did not confer NNRTI resistance when present only in the p66 subunit of RT.  
However, N348L in the p51 subunit displayed decreased RNase H activity (Fig. 27B), increased 
AZT-MP excision (Fig. 28B) and ~6-fold nevirapine resistance over WT (Fig. 29, blue bar).   
The modeling study suggests that when the N348I mutation is present in the p51 subunit, 
the β14-β15 loop is farther away from the RNA template such that residues P345 and F346 do 
not make contact with the template (Fig. 25A, pink).  However, when leucine is present at this 
position, only the F346 is not in contact with the template (Fig. 25C, pink).  Therefore, it seems 
that the loss of contact between the F346 residue in the p51 subunit and the RNA template 
affects RNase H activity.  
In addition to NRTI resistance, these data suggest the NNRTI resistance is also associated 
with the decreased RNase H activity.  When taken in the context of my previous data, we can 
describe the following model (Fig. 30).  In the presence of NNRTIs, HIV-1 RT can shift from a 
polymerase-competent mode of binding, to an incompetent mode.  This accounts for decreased 
polymerization, accelerated appearance of shorter RNase H products and decreased excision of 
terminating nucleosides.  However, when N348I is present, it is able to compensate for the shift 
in the presence of NNRTIs and favor the polymerase-competent binding mode, allowing 
increased polymerization (NNRTI resistance), WT levels of RNase H cleavage and enhanced 
NRTI excision.  This may also explain why N348I has increased processivity and can bind 
shorter substrates for a longer period of time [204].  Because the primer grip region in the 
polymerase domain is more valuable in RT-T/P association than the grip region in the RNase H 
domain [35], RT may be able to remain bound to the shorter T/P longer when the polymerase  
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competent mode is favored.  Additional experiments need to be performed to determine if the 
polymerase activity is, in fact, moved from the 3’-end of the DNA primer both in the absence 
and presence of an NNRTI as well as in the presence of the N348I mutation. 
 
 
Figure 30. N348I confers NNRTI resistance by favoring a polymerase-competent binding mode. 
RT is shown with the polymerase (dark blue) and RNase H (red) active site (gray circles).  In the absence of 
inhibitor, RT favors binding to a T/P substrate with a recessed 3’ DNA end in a polymerase competent mode.  When 
an NNRTI binds to RT, it causes RT to favor sliding into a polymerase-incompetent mode, where the active site is 
not positioned for polymerization and the RNase H active site is closer to the 5’ end of the RNA template.  In the 
presence of the N348I mutation, RT favors the polymerase-competent mode of binding, which decreases the 
appearance of smaller RNase H cleavage products and allows greater levels polymerization (and excision of 
NRTIs). 
7.2 PUBLIC HEALTH SIGNIFICANCE 
Since the approval of delavirdine in 1996, NNRTIs have been used in combination with NRTIs 
to maintain low plasma viremia and to delay the onset of drug-resistant mutants [143, 253].  
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Globally, NNRTI-containing regimens are now the most widely prescribed combinations for 
initial therapy [177].  Currently, many clinicians choose to prescribe the NNRTI-based regimens 
in lieu of those containing a protease inhibitor due to the metabolic side effects associated with 
protease inhibitors (i.e. lipodystrophy) and the low cytotoxicity of NNRTIs [254-255].  For 
example, nevirapine is safe for use during pregnancy and, therefore, has been recommended for 
the prevention of mother-to-child transmission [256-257].  The World Health Organization also 
includes NNRTIs in their antiretroviral regimen for developing nations due to their low cost 
(relative to other options) and their potency [258].   
In light of the popularity of NNRTI-containing regimens, it is important to understand the 
mechanisms by which they inhibit HIV-1 as well as the mechanisms by which RT can overcome 
these therapies.  Determining the mechanisms of resistance can allow the development of 
inhibitors with greater potency against resistance virus and possibly delay the onset of resistance.  
Elucidating how the interplay between these mutations affects RT function is necessary for the 
treatment of ARV-experienced patients as well as the development of new, effective therapies.  
This study and previously published work demonstrating the importance of RNase H activity in 
resistance to NRTIs as well as NNRTIs highlights new drug targets as well as the importance of 
the interplay between the enzyme functions.  For example, because decreased RNase H activity 
can enhance resistance to NRTIs, therapies which inhibit virus replication by inhibiting RNase H 
activity will facilitate NRTI resistance.  However, the acceleration of RNase H activity may 
inhibit viral replication by prematurely removing the RNA template prior to strand transfer or by 
having effects on primer RNA removal.  Understanding the mechanisms by which RTIs function 
in the context of reverse transcription is vital to our ability to curb virus replication, especially 
when these compounds are used in combination therapy. 
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Additionally, transmission of RTI-resistant virus has been increasing.  To allow 
physicians to make the best choice for the treatment of their patients, a full understanding of 
clinically significant mutations is needed.  The currently available drug-resistance data base is an 
important tool to preventing rebounding virus but it needs to be expanded to include other 
regions of RT such as the connection and RNase H domains.  The work presented demonstrates 
that resistance can be present in the C-terminal domain of RT and should be considered during 
treatment. 
7.3 FUTURE DIRECTIONS 
Although this study adds to the field of drug resistance, a deeper understanding of these 
observations in the context of current therapy is necessary to evaluate the additional mechanisms 
by which NNRTIs inhibit HIV-1 RT and consequences of mutations that can alleviate this 
inhibition. 
7.3.1 Mechanism(s) by which NNRTIs inhibit RT and reverse transcription 
This work demonstrates that NNRTIs are inhibiting RT by a mechanism that was previously 
disregarded.  The interaction of RT with the RNA/DNA T/P substrate during reverse 
transcription provides different functions and binding modes for RT.  Although a shift in the 
binding mode of RT occurs on both T/P systems, this effect was highlighted on the RNA 
template.  Certain steps during reverse transcription that require multiple functions of RT have 
not been explored in the context of an NNRTI and may be particularly sensitive to inhibition by 
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this class of compounds.  For example, it is now understood that NNRTIs cause RT to bind 
differently to T/P and that RNase H activity is perturbed.  Steps during reverse transcription 
during which RT relies on the coordinated functions of RNase H activity and polymerase 
activity, may be uniquely affected by NNRTIs and/or RNase H modulating mutations.   
The process of strand transfer requires both RNase H and polymerase activity.  As 
described in section 1.1.3.2, the models proposed for mechanism of strand transfer rely heavily 
on RNase H activity.  Enhancement of this function (by mutation or NNRTI) could cause 
premature dissociation of RT prior annealing of the template acceptor or alter the formation of 
secondary structures which enhance the strand transfer events [37].  Studies have already 
demonstrated that NNRTI-resistant mutations are more resistant during the process of strand 
transfer [210] suggesting that strand transfer may be inhibited during reverse transcription. 
Recent data also demonstrates that NNRTIs can affect RNA primer removal [54], an 
important process to determine the ends of the LTR for proper integration into the host cell 
genome.  The study presented here as well as single-molecule FRET studies show that the 
presence of NNRTIs can cause RT to change its position on the T/P.  Acceleration or alteration 
of the cleavage position during primer removal could alter the LTRs and inhibit integration.  
Therefore, in vitro assays to evaluate the effect of NNRTIs specifically on strand transfer and 
primer removal need to be developed. 
7.3.2 More questions about N348I and the connection between decreased RNase H 
activity and NNRTI-resistance. 
Although the basic mechanism of NNRTI resistance conferred by N348I has been described, this 
model can be further confirmed by additional FRET experiments.  A similar FRET analysis 
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using RT with the N348I mutation (and other such mutations which decrease RNase H activity 
and increase NNRTI resistance) would confirm our model.  Additionally, the model suggests that 
the actual rate of RNase H cleavage is not altered by the N348I mutation.  This assumption can 
be confirmed by pre-steady state analysis of the initial polymerase-dependent cleavage as well as 
the rate of subsequent polymerase-independent cleavages. 
Due to the lack of a relevant crystal structure, the structural effects of the N348I mutation 
in the p51 subunit that cause RT to favor the polymerase-competent binding mode is still 
unknown.  Crystal structures with N348I RT may provide clues to this.  However, in the absence 
of the T/P connection with both active sites, a structure may be inconclusive.   
7.3.3 Resistance Mutations in Non-subtype B 
Although subtype B is most prominent in the industrialized world, subtype C is most prevalent 
overall [7].  Despite this, subtype B clones have been used in most studies for the development 
of effective antiretroviral inhibitors as well as to understand drug resistance mechanisms.  This 
raises the question of whether individuals infected with non-subtype B viruses will fully benefit 
from current treatments.  A growing body of evidence suggests that different subtypes may 
respond differently to therapeutic interventions [259].  Furthermore, the presence of 
polymorphisms in non-B subtypes which are considered secondary resistance mutations in 
subtype B [260-262], supports the idea that the acquisition of drug resistance mutations might be 
enhanced in non-B subtypes of HIV-1.  For example, it has been demonstrated that the genetic 
variation at NNRTI-resistance positions such as V106M and A98S was substantially greater in 
subtype C-infected patients than in subtype B-infected patients [263].  Accordingly, V106M 
seems to be a signature mutation in subtype-C patients treated with efavirenz [264].  Moreover, 
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one study conducted in Uganda, revealed that selection of genotypic mutations associated with 
resistance occurred more frequently in women infected with subtype D than in women infected 
with subtype-A viruses [265].  Additionally, intrinsic difference in the subtypes may lead to 
differential resistance among them.  One study found that subtype D had diminished drug 
sensitivity as a result of more rapid growth kinetics as compared to subtypes A, B, C and E 
[266], highlighting that there are fundamental differences between subtypes.  These observations 
suggest that subtype B may not be an appropriate model for the study of all HIV-1 resistance 
development.   
The development of specific mutations in various subtypes is also worth investigating.  
Recent studies have already demonstrated the development of N348I in subtype C virus in South 
Africa [267].  However, more data is needed to properly correlate the increase in the frequency 
of this mutation with specific therapies as well as co-selected mutations.  This would suggest if 
the N348I mutation also appears with TAMs, NNRTI resistance mutations and M184V as has 
been determined with this mutation in subtype B.  Additionally, biochemical evaluation of the 
mutation in the context of the subtype C RT would be important to further understand the 
development and mechanisms of resistance in non-subtype B viruses.  Because the genotypes of 
the different subtypes lead to different replication kinetics, the mutational pathways taken in 
subtype C as compared to subtype B may be different.  Therefore, the compensation we see for 
antagonism by N348I in the presence of TAMs and mutations such as L74V, M184V and Y181C 
may not be relevant in the context of subtype C. 
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